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Abstract 
Calcium sensitizers are a novel class of inotropic agents that appear advantageous for treating acute 
decompensated heart failure and other low output heart failure situations relative to conventional 
inotropic drugs, which act primarily by increasing intracellular calcium mobilization in cardiac 
myocytes. Levosimendan, the only calcium sensitizer in clinical use at the moment, mediates its 
cardiac effect by the calcium sensitization of the contractile protein troponin C. Levosimendan binds 
to the calcium-saturated N-terminal domain of troponin C in cardiac muscle and stabilizes the 
troponin molecule, with subsequent prolongation of its effect on the contractile proteins. Besides 
increasing the strength of cardiac contractions, levosimendan exerts vasodilatory effects through 
opening of the sarcolemmal and mitochondrial ATP-sensitive potassium channels. The major 
elimination route of levosimendan is conjugation with glutathione to cysteine and cysteinylglycine 
conjugates. A minor metabolism route is reduction of levosimendan in intestine by bacteria into 
metabolite OR-1855, which is further acetylated to OR-1896. Although this is minor pathway, it is 
pharmacologically very important since OR-1896 is a long-lasting metabolite sharing the 
pharmacological properties of the parent compound. Levosimendan is currently used only as a 24-h 
systemic infusion.  
This study aimed at exploring the cardiovascular effects of oral calcium sensitizers in two different 
animal models of heart failure, namely in hypertensive and salt-sensitive Dahl/Rapp SS rats on a high-
salt diet (a model of hypertensive heart failure with preserved systolic function) and in spontaneously 
diabetic Goto-Kakizaki rats with experimental myocardial infarction induced by coronary artery 
ligation (a model of post-infarct heart failure with impaired systolic functions).  
We were able to demonstrate that in Dahl/Rapp SS rats both levosimendan and OR-1896 prevented 
mortality, produced a transient decrease in blood pressure, prevented cardiac hypertrophy and 
improved cardiac contractility. These beneficial effects were associated with decreased cardiac atrial 
natriuretic peptide mRNA expression, a marker of pressure/volume overload, attenuation of oxidative 
stress, inflammatory response and cellular senescence. In Goto Kakizaki rats, levosimendan and OR-
1896 prevented MI-induced systolic heart failure, pronounced cardiac hypertrophy in the remote area, 
and sustained cardiomyocyte apoptosis. The beneficial effects of calcium sensitizers were associated 
with decreased myocardial atrial natriuretic peptide, inflammatory interleukin 6 and fibrogenic 
connective tissue growth factor mRNA expressions, and corrections of MI-induced disturbances in 
calcium-handling proteins (sarco/endoplasmic reticulum Ca2+-ATPase 2a, Na+/Ca2+-exhcanger). 
In conclusion, our findings suggest a therapeutic role for oral calcium sensitizers in the prevention of 
hypertension-induced heart failure with preserved systolic function as well as in the prevention of 
post-infarct heart failure with decreased systolic function. 
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1 Introduction 
Heart failure, also known as congestive heart failure, is a serious condition where the heart is unable 
to maintain sufficient blood flow for body’s needs in different situations. Compensating mechanisms 
can initially hide failure in cardiac pumping capacity, but eventually full-blown syndrome will 
severely hinder the ability to cope with everyday tasks. Approximately 1-2% of the population in the 
Western world is affiliated by heart failure, with the prevalence strongly increasing with age. In the 
year 2020 prevalence of heart failure is estimated to increase by 20%, with a 40-50% increase in in-
hospital time. (American heart association, 2004, Kupari and Lommi, 2004) Since most of the costs 
caused by heart failure are due to repeated hospital admissions, the burden to an already heavily 
encumbered health care system will be marked. 
Survival after a cardiac event is impaired in the presence of preceding diabetes. Nowadays, the most 
common form of diabetes mellitus, type 2 diabetes, affects over 170 million people worldwide, with 
prevalence increasing dramatically (Campbell, 2009, Ginsberg and MacCallum, 2009). Type 2 
diabetes is described as a metabolic syndrome in which the body develops a resistance to insulin and 
changes occur in fat metabolism. This leads to elevated blood glucose levels, quite often combined 
with dyslipidemias, and finally to chronic tissue damage and target organ dysfunction. Type 2 
diabetes is known to be a major risk factor for cardiovascular diseases; the risk for cardiovascular 
disease is enhanced 2- to 5-fold in type 2 diabetic patients, more than 50% of whom will die from 
cardiovascular causes. (Laakso, 2001) For example, mortality for myocardial infarction is higher and 
survival worse in diabetic than non-diabetic patients despite similar-sized infarctions (Klamann et al., 
2000, Haffner et al., 1998, Mukamal et al., 2001). 
Heart failure is not an isolated condition; the underlying causes for heart failure are cardiovascular 
diseases, such as coronary artery disease, myocardial infarction, hypertension and valvular disease, 
and rarely some other conditions, such as viral infections, genetic disorders or intoxications. 
Hypertension, diabetes and myocardial ischaemia are common risk factors for the heart failure with 
preserved systolic function, which is pathophysically characterized with excessive fibrosis and 
myocyte hypertrophy, leading to impaired left-ventricular filling and diastolic stiffness. (Krum and 
Abraham, 2009) Systolic heart failure results after damage to the cardiac muscle, such as myocardial 
infarction, impairs heart’s ability to maintain sufficient pumping. 
Acute heart failure develops when sudden cardiac event, such as myocardial infarction, myocarditis or 
pumping disorder caused by severe arrhythmia, hinders cardiac pumping capacity. Patients suffer 
from severe shortness of breath because of pulmonary oedema due to compromised pumping of the 
left ventricle. In the worst case, acute heart failure can be fatal, but normally it is a treatable condition, 
sometimes even with full recovery. (Heikkilä et al., 2008) 
Chronic heart failure can occur suddenly, but typically it develops over a long period of time. At first 
mild, hardly detectable symptoms manifest only during stress. Symptoms then become progressively 
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more severe, with shortness of breath occurring even at rest. Chronic heart failure often develops 
rapidly to acute pulmonary oedema due to excess cardiac stress, such as infectious disease, physical 
or emotional stress or arrhythmia. In spite of development in modern pharmacology, chronic heart 
failure remains a fatal disease. (Heikkilä et al., 2008) 
Approximately half of the heart failure patients have contractile failure and dilated heart, known as 
systolic heart failure, and the remaining patients have heart failure with preserved ejection fraction, 
which includes relatively normal contraction and non-dilated but often hypertrophied heart. Heart 
failure can also be divided into systolic and diastolic heart failure, depending on the failing ventricle. 
Independent diastolic heart failure is a rare condition; generally heart failure is considered to be 
failure in systolic functions, potentially combined with simultaneous diastolic failure. (Heikkilä et al., 
2008) 
Despite marked improvements, such as cardiac transplant and promising stem cell treatments, (for 
review see (Daneshmand and Milano, 2009, Vertesaljai et al., 2008)) In past decades, treatment of 
heart failure remains relatively ineffective and existing damage to the heart can not be repaired. The 
purpose of this study was to clarify the underlying mechanisms in development of heart failure during 
hypertensive heart disease and in the diabetic post-infarct remodelling. This study also aimed to 
evaluate the effects of oral levosimendan treatment and its potential preventive role in development of 
heart failure.  
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2 Review of the literature 
2.1 Heart failure 
2.1.1 Epidemiology and prevalence 
The most common underlining causes of heart failure in the Western world are coronary artery 
disease and hypertension. In newly diagnosed patients with heart failure, 50% have coronary artery 
disease, 50% hypertension and 80% coronary artery disease, hypertension or both. Myocardial 
infarction is also major risk factor for heart failure; approximately 17% of patients develop heart 
failure. Other important risk factors are valvular disease, cardiomyopathies and diabetes. Predominant 
risk factors for rare, independent right ventricular failure are chronic pulmonary disease, myocardial 
infarction in the right ventricle, recurrent pulmonary embolus and primary pulmonary hypertension. 
(Kupari and Lommi, 2004) 
Heart failure is a rarely manifested in patients younger than 50 years, but its prevalence grows rapidly 
with age. Due to ageing of the global population prevalence of heart failure is on the rise, especially in 
developing countries with limited health and social care resources. According to the Framingham 
study, in individuals over 40 years the lifetime risk of developing heart failure is 1 to 5. (Lloyd-Jones 
et al., 2002) 
Heart failure remains a fatal disease; the one-year mortality of newly diagnosed cases is roughly 25%. 
The long-term survival is poor, with 70% of those under 65 years diagnosed with heart failure dying 
over the next eight years. Total-mention mortality in 2004 was over 280 000 in USA alone, 1 in 8 
deaths had heart failure mentioned in death certificates. (Rosamond et al., 2008)Treatment of heart 
failure is expensive, according to The social insurance institution of Finland heart failure related drug 
costs alone were over 200 million € in year 2005.  
 
2.1.2 Clinical symptoms and diagnosis 
Shortness of breath during physical activity is one of the first symptoms of the heart failure; however, 
it does not necessarily indicate failure in cardiac functions. Other symptoms include fatigue, swelling 
of feet and ankles as well as related nocturia. In addition, changes in psychological functions, such as 
memory problems, restlessness and confusion, are common, especially in the elderly. Swelling of the 
upper abdomen, nausea, lack of appetite and changes in bowel functions are caused by congestion in 
systemic veins, liver and bowel. (Heikkilä et al., 2008) 
Diagnosing heart failure is challenging; half of heart failure diagnoses made in primary care are 
incorrect (Remes et al., 1991). Diagnosis of heart failure is based on careful clinical observations, 
including verification of failing heart functions, clarification of underlying causes, such as lifetime 
habits or storage diseases, and associated diseases. (Jessup et al., 2009, Schocken et al., 2008, Hunt et 
al., 2009, Heliö et al., 2003) 
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Simplified diagnostic criteria for heart failure in primary care includes existing cardiovascular disease 
and three of the following symptoms (Kupari and Lommi, 2004):  
1. Shortness of breath or fatigue under ordinary stress 
2. Third heart sound or resting pulse over 90 bpm 
3. Increased heart size in chest X-ray 
4. Elevated pressure in vena jugularis or congestion of pulmonary veins in thorax X-ray. 
The diagnosis can be supplemented with determination of serum brain natriuretic peptide (BNP), 
electrocardiogram, echocardiography and experimental treatment with diuretics. (Kupari and Lommi, 
2004) 
Severity of heart failure is often described using the NYHA (New York Heart Association) 
classification (Levin et al., 1994) as follows: 
1. NYHA I: No limitations in activities, no symptoms in ordinary activities 
2. NYHA II: Mild limitation of activity, mild symptoms in ordinary activities 
3. NYHA III: Severe limitation in activities, symptoms during light activities 
4. NYHA IV: Severely compromised capacity in all activities, symptoms manifest also during 
rest. 
 
2.1.3 Treatment 
Prevention of development or deterioration of existing heart failure and available treatment options 
for a failing heart are based on five major components (for review, see (Ruvinov et al., 2008)): 
• Cardioprotection: prevention of progressive loss of cardiomyocytes via anti-apoptotic 
approaches or induction of mechanisms promoting survival. 
• Inflammation: modulation of pro- and anti-inflammatory responses in induction of tissue 
healing while avoiding negative inflammatory effects. 
• Extracellular matrix remodelling and cardiac fibrosis: prevention of deleterious remodelling 
and excessive fibrosis formation. 
• Angiogenesis: enhancement of tissue healing and prevention of ischaemic damage by 
increasing blood supply to ischaemic areas. 
• Cardiomyogenesis: induction of cardiomyocyte regeneration in an attempt to repair existing 
damage, such as stem cell transplants or growth factor-based therapies. 
One of the main factors in treating heart failure patients is lifestyle change. Suitable physical activity, 
weight loss in obese patients, decreased salt in food, cessation of smoking and moderate alcohol 
consumption are cornerstones in the daily life of heart failure patients. The underlying cause for heart 
failure should also be treated when possible with revascularization, valve surgery and correction of 
arrhythmias. Treatment of other associated diseases, such as kidney failure, chronic obstructive 
pulmonary disease and atrial fibrillation, must be addressed. Maintaining adequate cardiovascular 
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nursing is crucial in monitoring the effectiveness of treatment and patient compliance. (Kimmelstiel et 
al., 2004, Koelling et al., 2005) 
Several pharmacological methods are available for treating the chronic heart failure (Figure 1). In an 
acute situation, the focus is on increasing cardiac contractility and improving haemodynamics. When 
carried out for a longer time, inotropic support is considered harmful, and mechanisms responsible for 
the failing heart are then treated with following goals (Kupari and Lommi, 2004): 
1. To suppress increased activity of the sympathetic nervous system and renin-angiotensin 
system (RAS) by β-blockers, ACE-inhibitors, AT1-receptor blockers and aldosterone 
antagonists in different combinations. 
2. To decrease workload by lowering blood pressure to the lowest possible level with ACE-
inhibitors, AT1-receptor blockers, vasodilating β-blockers or in selected cases calcium 
channel blockers felodipine and amlodipine. 
3. To decrease elevated filling pressure with diuretics and nitrates. 
4. To prevent of cardiomyocyte ischaemia by β-blockers and nitrates. 
 
Figure 1. Possible pharmacological treatment options for chronic heart failure. Modified from (Heikkilä et al., 
2008). 
To all patients with heart 
failure 
• ACE inhibitor 
• Diuretics 
• β-blocker 
• spironolactone Atrial fibrillation 
• Digitalis 
• Warfarin 
• Amiodarone 
Angina pectoris 
• Nitrate 
Intolerance to ACE-
inhibitor 
• AT1-receptor 
blockers 
Inefficient response to 
treatment 
Congestion 
• Diuretics 
• Digoxin 
• i.v. diuretic or low dose 
dopamine 
No congestion 
• Increase ACE-
inhibitor dosing 
• Digoxin 
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Drugs affecting to activated RAS, such as ACE-inhibitors and AT1-receptor blockers, should be given 
to all patients with decreased function of the left ventricle (ejection factor less than 40-45 %), even 
though patient would be asymptomatic. They are especially useful to patients with history of 
myocardial infarction and hypertension. ACE-inhibitors have been found to improve prognosis in all 
states of heart failure, in non-responding patients with severe heart failure AT1-receptor blockers can 
be combined into treatment. (Swedberg et al., 1999, Pfeffer et al., 2003) 
Aldosterone antagonism, epleronone or spironolactone, can be useful in treating patients with non-
responding, severe heart failure but that requires plasma potassium monitoring. (Pitt et al., 2005, Pitt 
et al., 1999) 
β-blockers, with adequate dosing, should be used on all heart failure patients, despite of the aetiology, 
due to the harmfulness of increased sympathetic activity to the heart. They improve prognosis and 
prevent mortality, especially beneficial they are to the patients with ischemic heart disease or 
hypertension. (Packer et al., 1991, Lichstein et al., 1990) The beneficial, long-term effects of β-
blockers are mediated by downregulation of the β-adrenergic receptors, increased inhibitory G-protein 
and G-protein-coupled receptor kinase 2 signalling and amelioration of the abnormalities of 
excitation-contraction-coupling proteins. (Lowes et al., 2002, Brodde, 2007) Alleviation of the 
symptoms with β-blocker treatment is slow; the beneficial effects may take 1-2 months to come 
forward. In elderly patients (<75-80 years), β-blockers is less beneficial than in younger patients.  
Diuretics are used in the treatment of heart failure in patients with liquid retention. To prevent 
harmful effects, diuretic dose should lowest effective. Diuretics and ACE inhibitors have synergistic 
effect, and administration of diuretics on the patients with ACE inhibitors should be started with care. 
(Kupari and Lommi, 2004) 
Anticoagulants are used on patients with increased risk for thromboembolic complications; however 
evidence in effectiveness of warfarin treatment in prevention of thromboembolia is contradictory. (for 
review (Ahnert and Freudenberger, 2008)) Acetylsalicylic acid (ASA) can be given to patients with 
coronary artery disease or type 2 diabetes. (Kupari and Lommi, 2004) 
Nitrates or calcium channel blockers do not have evidence-based effect on treatment of heart failure. 
However, they can be used heart failure patients with coronary artery disease or hypertension. (Kupari 
and Lommi, 2004) 
Digoxin was the only effective drug for treatment of heart failure for many centuries. Nowadays its 
use has declined and it is mainly used in combination with β-blockers for the patients with atrial 
fibrillation. Digoxin has no effect on mortality but it increases time out of hospital. (The Digitalis 
Investigation Group, 1997)  
The asymptomatic ventricular extrasystole is a common phenomenon in heart failure and normally 
requires no treatment. Of currently available drugs used for arrhythmias, only amiodarone is suitable 
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for the treatment of heart failure, because it has no detrimental effect on left ventricular functions. 
Amiodarone has been shown to reduce severe arrhythmias and mortality, but it has no effect on all-
cause mortality. (Singh et al., 1995) However, atrial fibrillation should be prevented actively with β-
blockers and amiodarone. 
 
2.1.4 Mechanisms of heart failure 
Fundamental understanding of the biology of heart failure is lacking, mainly due to the heterogeneity 
of underlying mechanisms. Several mechanisms have been proposed to result in failing cardiac 
functions, with many of them manifesting in combination in clinical settings (Figure 2). 
 
 
Figure 2 Mechanisms related to development of heart failure with possible pharmacological treatment options. 
Modified from (Heikkilä, et al 2008). 
 
2.1.4.1 Single gene mutations and genetic polymorphisms 
Several single gene mutations subject patients to heart failure. The most common inherited mutations 
leading to cardiomyopathies are in genes coding sarcomeric proteins, such as beta myosin heavy 
chain, myosin binding protein C and cardiac troponin C (hypertrophic cardiomyopathy, HCM) and 
actin and dystrophin (dilated cardiomyopathy, DCM). Also mutations in genes coding energy 
production and regulation, mainly in mitochondria, Ca2+ cycling and transcriptional regulators, have 
been reported. (for review see (Hershberger et al., 2009)) 
Genetic differences affect not only the severity of heart failure but also the responsiveness to 
treatment. For example, among heart failure patients with either arginine or glycine in position 389 of 
β1-receptor protein, those with arginine-encoding variants have lower mortality and fewer 
hospitalizations, whereas patients with glycine-encoding variants show little response to therapy 
(Mialet Perez et al., 2003). Ethnicity also plays a role in differences between individuals. 
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Pathophysiologic bases of heart failure in black Americans have been postulated to be rather 
endothelial dysfunction and/or reduced nitric oxide bioavailability than neurohumoral activation. 
(Yancy, 2005) This is further supported by black American’s better response to a combined treatment 
of hydralazine and isosorbiside than Caucasian patients (Yancy et al., 2007, Taylor et al., 2004). 
 
2.1.4.2 Renin-angiotensin-aldosterone-system 
In severe heart failure the RAS system is activated to maintain efficient tissue perfusion and 
glomerular filtration. Besides weakened kidney perfusion, other activating factors for the RAS system 
are increased sympathetic activity and decreased sodium level in distal tubules. In normal situation, 
activity of the RAS system is controlled via atrial baroreflex and natriuretic peptides, but this 
inhibitory capacity declines in a failing heart producing a positive shift towards RAS activation. Over 
time, the originally beneficial RAS activation becomes detrimental to the heart. (Danilczyk and 
Penninger, 2006) 
Responses to the activated RAS system are mediated through binding of angiotensin II to angiotensin 
receptors, AT1 and AT2. AT1 receptor is a dominant form in cardiac tissue, and its activation promotes 
vasoconstriction, hypertrophy, fibrosis, thrombosis and atherosclerosis. Activation of the AT2 receptor 
mediates counterbalancing functions such as vasodilatation and antihypertrophic and antifibrotic 
actions. Activated RAS system also increases both local and systemic aldosterone concentration, 
which further elevates water and sodium retention, increases sympathicus-activated peripheral 
responses, stiffness of large vessels, fibroblast proliferation and cardiac and smooth muscle cell 
collagen synthesis and diminishes baroreflexes. (Danilczyk and Penninger, 2006) 
Although systemic RAS is activated at later stage of heart failure, the local cardiac RAS system is 
activated long before any increase can be seen in plasma levels (Bader and Ganten, 2008, Krop and 
Danser, 2008, Kumar et al., 2009). 
 
2.1.4.3 Increased sympathetic signalling 
Cardiac adrenergic system regulates cardiac functions, allowing heart to adapt to dramatically 
different workloads in a matter of seconds. This system, presumably evolved as a survival response to 
trauma and blood loss, gives a considerable advantage to short-term survival. However, these 
compensatory mechanisms are also activated when heart function declines for any reason in an 
attempt to maintain sufficient organ perfusion. (Bohm et al., 1997) 
In the early stages of developing heart failure, increased activity of the sympathetic nervous system 
compensates the decline in cardiac functions. However, a high level of adrenergic stimulation is 
extremely cardiotoxic (Rona, 1985). As the heart becomes progressively less sensitive to stimulatory 
sympathetic activity in a protective manner, chronic stimulation by circulatory catecholamines leads 
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to a vicious circle that worsens the clinical condition and contributes to increased cardiac damage. 
(Bohm et al., 1997) 
Especially damaged by sympathetic signalling is the peripheral vasculature, where, unlike in the heart, 
no protective mechanisms, like β-receptor desensitization or uncoupling of β-receptor-mediated 
signalling are present. Increased vasoconstriction leads to hypoperfusion and anoxia of the tissues, 
increasing anaerobic metabolism and workload of the left ventricle, which further stresses a failing 
heart. Increased noradrenalin levels also stimulate development of hypertrophy (for review, see 
(Osadchii, 2007)), mainly via α-receptors and fibrosis making the heart more prone to arrhythmias. 
Sympathetic activity also has a synergistic effect on the renin-angiotensin-aldosterone system; by 
increasing renin excretion (Osadchii, 2007). 
In patients with heart failure, plasma noradrenalin concentration is increased compared with normal 
controls due to leakage from nerve endings and decreased clearance. Increased plasma concentration 
correlates strongly with severity and prognosis of the disease; increased noradrenalin concentration 
already in an asymptomatic functional disorder of the left ventricle predicts development of heart 
failure, ischaemic heart events and increased risk of death. (Benedict et al., 1996) In a failing heart, 
also the β-receptor subtypes undergo down regulation resulting in a suboptimal ratio of β1:β2 receptors 
of 50:50 instead of the normal 75:25 (Port and Bristow, 2001). 
 
2.1.4.4 Ca2+ handling and regulation of excitation-contraction coupling 
Altered calcium handling plays a major role in development of heart failure. In many cases, defects in 
calcium handling precede depressing function; for example, in compensated hypertrophy this is seen 
as impaired relaxation in the presence of normal or increased systolic parameters. (Gwathmey et al., 
1987a) Reduced peak systolic Ca2+ concentration, elevated diastolic Ca2+ concentration and prolonged 
duration of Ca2+ transient are common calcium handling features in a failing heart. Defects in calcium 
handling are due to abnormalities in function or expression of calcium handling proteins, increase in 
space between L type Ca2+ channels and ryanodine receptors (RyRs) and velocity of synchrony of 
Ca2+ release. (Gwathmey et al., 1987b, Gwathmey and Hajjar, 1990b, Gwathmey and Hajjar, 1990a, 
Gwathmey and Hajjar, 1990c, Piacentino et al., 2003) 
Impaired relaxation and abnormal force-frequency in both isolated muscles and myocytes from failing 
hearts suggest a deficiency in Ca2+ reuptake to the sarcoplasmic reticulum. A reduction in SERCA2 
mRNA and protein level or SERCA2 protein activity or altered SERCA2 to NCX ratio has been 
found in both human and experimental studies (Zarain-Herzberg et al., 1996, Seki et al., 2003a, 
Schmidt et al., 1998, Okayama et al., 1997, Meyer et al., 1995, Aoyagi et al., 1999). 
Hypophosphorylation of phospholamban (PLN) via desensitization of the β-adrenergic signalling 
pathway or activation of the RAS system further reduces SERCA2 activity, decreasing contractility 
(Dash et al., 2001, Zheng et al., 2004). Interestingly, improvement in cardiac functions and calcium 
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handling can be achieved via gene transfer of SERCA2 in different experimental models (Miyamoto 
et al., 2000, del Monte et al., 1999, del MonteF. et al., 1999). 
 
2.1.4.5 Cardiac hypertrophy 
Cardiac hypertrophy, characterized by increased cell volume and cardiac mass, is an adaptive 
mechanism in case of increased volume or pressure load. Although cardiac hypertrophy, especially 
left ventricular hypertrophy, is a powerful risk factor for cardiac events (Artham et al., 2009), all 
forms of hypertrophy are not pathological; during development hypertrophy is major determinant of 
growth. Also exercise-induced hypertrophy mediates positive effects via the increased cardiac output 
required by physical activity. In developmental and physiological hypertrophy, the growth between 
wall thickness and chamber volume is balanced, while pathological hypertrophy is characterized by a 
thickened ventricular wall with a concomitant decrease in ventricular chamber dimension. (Dorn, 
2007) Hence, pathological overgrowth can severely hinder cardiac pumping potential. 
Cardiac hypertrophy can be divided into two separate forms, concentric and eccentric hypertrophy 
(Figure 3). Concentric hypertrophy, induced by pressure overload, is characterized by increased wall 
thickness with thickened myocytes but without a change in chamber radius. However, in eccentric 
hypertrophy, mediated by volume overload, chamber volume grows with increased length of 
individual myocytes and decreased wall thickness. Eccentric hypertrophy is typically induced by 
myocardial infarction, while chronic hypertension and aortic stenosis are the main risk factors for 
concentric hypertrophy. Neurohumoral factors, such as angiotensin II, aldosterone, adrenalin and 
endothelin-1, are also important stimulators of hypertrophic responses, and the corresponding receptor 
antagonists and inhibitors can blunt their effects (Gupta et al., 2007, Lorell and Carabello, 2000). 
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Figure 3. Mechanisms of cardiac hypertrophy. Modified from (Gupta et al., 2007) 
 
2.1.4.5.1 Mechanisms involved in heart failure-related cardiac hypertrophy 
Hypertrophic stimuli, such as wall stress, vasoactive peptides, neurohormones, and growth factors, 
activate a complicated signalling network eventually leading to hypertrophic response. Mechanical 
stress sensory system, G-protein activation and several signalling cascades, such as calcineurin or 
mitogen activated protein kinase (MAPK)-mediated pathways are all important regulators for cardiac 
hypertrophy, and their roles are discussed below. (For review see (Gupta et al., 2007, Barry et al., 
2008, Heineke and Molkentin, 2006, Pikkarainen et al., 2004)) 
Mechanical stress of the ventricular wall is detected via specified internal sensory systems. Integrins 
connect the intracellular cytoskeleton to the extracellular matrix, and they have been speculated to 
mediate mechanical stress signals (Brancaccio et al., 2003, Donker et al., 2007). Two classes of 
molecules, structural and signalling proteins, mediate integrin-actin associations. The structural 
proteins consist of the integrins and cytoplasmic molecules such as vinculin and talin. The signaling 
proteins include a number of enzymes and adaptor molecules, responsible for initiation of 
downstream molecule activation, such as Akt, RAS and ERK1/2, which execute the hypertrophy 
program. (Brancaccio et al., 2006) Impairment of this sensory system can protect from pathologic 
hypertrophy as mice lacking the four-and-a-half LIM domains 1 (Fhl1), element of sensory apparatus 
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of sarcomeres, represent blunted response to hypertrophic stimuli and conserved cardiac capacity after 
pressure overload caused by aortic banding (Sheikh et al., 2008). 
G protein activation plays an important role in the cardiovascular system. Several neurohormonal 
mediators, such as angiotensin II, endothelin-1 and adrenoreceptors, are coupled with different G 
proteins of Gαq/α11 subclass. Gαq/α11 coupling seems to be involved specifically in pathological 
cardiac hypertrophy, as overexpression of wildtype Gαq leads to severe cardiac hypertrophy and heart 
failure (D'Angelo et al., 1997), and its inactivation counteracts from these detrimental effects 
(Wettschureck et al., 2001). However, activation of Gαq/α11 can also promote prosurvival and anti-
apoptotic effects through Akt activation, which is independent of hypertrophy-promoting functions 
(Howes et al., 2006). Inhibition of beta-adrenergic receptor signalling has been shown to reduce 
hypertrophic response induced by chronic overload (Plante et al., 2004, Paradis et al., 2000). Also 
transition from cardiac hypertrophy to chronic heart failure in the presence of simultaneous chronic 
pressure overload and loss of cardiac mass in ischaemic hearts is affected by Gi-mediated signalling 
pathways (Kouchi et al., 2000). 
Phosphoinositide 3-kinases (PI3K) and Akt regulate cardiomyocyte growth, survival and metabolism 
(Matsui et al., 2003). Activation of PI3K increases the amounts of phosphatidylinositol 3,4,5-
triphosphate and phosphatidylinositol 3,4-triphosphate in a cell membrane, resulting in 
phosphorylation and activation of Akt. Akt is an important mediator of cardiomyocyte growth. 
Indeed, transgenic overexpression of Akt has been demonstrated to induce hypertrophic growth in the 
heart (Matsui et al., 2003, Shioi et al., 2002). 
Calcineurin, a Ca+ -dependent serine/threonine protein-phosphatase, activates a nuclear factor of 
activated T cell (NFAT)-dependent hypertrophic response, which has been speculated to be an 
important regulator of maladaptative hypertrophy (Heineke and Molkentin, 2006). Calcineurin, which 
is activated by elevated intracellular calcium, binds to NFAT. Once dephosphorylated, NFAT 
translocates into cytoplasm and initiates prohypertrophic gene expression. Calcineurin-NFAT 
signalling is controlled by several kinases, such as p38 and c-Jun N-terminal kinases (JNKs), which 
phosphorylate NFAT and reduce hypertrophic response. (Braz et al., 2003, Liang et al., 2003) 
Inhibition of calcineurin activity has been shown to have beneficial effects on hypertrophy both in 
humans and in experimental models, but severe side-effects limit its use for treating larger 
populations (Wilkins and Molkentin, 2004). 
Mitogen-activated protein kinases (MAPK) play an important role in hypertrophic overgrowth. 
MAPK family members are involved in major biological processes such as cell growth, differentiation 
and apoptosis, and MAPK activation has been discovered in the heart in several different disease 
stages, e.g. hypertrophies with a different aetiologies and ischaemic/reperfusion injury (Kyriakis and 
Avruch, 2001a). The MAPK superfamily is grouped on following three categories: extracellular 
signal-regulated protein kinase (ERKs), JNKs and p38 MAPKs. In cardiomyocytes ERKs are 
activated by great variety of hypertrophic stimuli, including angiotensin II, endothelin 1 and several 
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growth factors, as well as mechanical stress. JNKs and p38 MAPKs are activated mainly via cellular 
stresses such as heat shock, oxidative stress, ischaemia and inflammatory cytokines. (Kyriakis and 
Avruch, 2001b, Muslin, 2008) Their actions are speculated to be mediated in prosurvival manner, and 
they might actually be negative regulators of hypertrophy (Heineke and Molkentin, 2006, Opie et al., 
2006). 
Protein kinase C (PKC) is universally important mediator; functioning downstream of almost all 
membrane-associated transduction pathways (Nishizuka, 1986). PCK isozymes are involved in 
several cardiac diseases, as well as cardiac injuries and ischemic postconditioning (Palaniyandi et al., 
2009). Expression of PKC subtypes, α, β and δ, is elevated through out the transition from the 
hypertrophic state to heart failure, but expression of PCKε is reduced in chronic failure (Koide et al., 
2003). 
 
2.1.4.6 Oxidative stress 
Mammalian heart is an obligate aerobic organ; at rest, it consumes 2- to 5-fold and during vigorous 
exercise over 20-fold more oxygen than the brain. Constant supply of oxygen is fundamental for 
cardiac functions. Severe ischaemic attacks will cause permanent damage to heart muscle. Oxygen 
level is also an important regulator of myocardial gene expression, nitric oxide (NO) bioavailability 
and generation of reactive oxygen species (ROS). (Giordano, 2005) 
ROS consist of free radicals, such as superoxide radical, hydroxyl radical and hydrogen peroxide. 
ROS can also be produced from NO, reaction between NO and superoxide radical forms 
peroxynitrite, a highly reactive radical. ROS can be generated via several mechanisms: xanthine 
oxidase, several different NADPH oxidases, cytochrome P450, cyclo-oxygenases and uncoupled NO 
synthases. An electron leak from mitochondrial respiratory chain and inflammatory cells are the main 
source of organelles for ROS. Production of ROS can also be induced by cytokines and growth 
factors, such as angiotensin II and tumour necrosis factor α (TNF-α). (Giordano, 2005) 
Several cellular mechanisms exist for prevention of ROS-induced damage, including enzymatic 
pathways such as catalase and glutathione peroxidases, superoxide dismutases and the thioredoxin 
system as well as non-enzymatic mechanisms of intracellular antioxidants such as vitamins E and C, 
lipoic acid and glutathione. These protective mechanisms maintain the balance between ROS and 
antioxidative defence, the so-called redox state of the cell. The pathological state of excess ROS 
production is known as oxidative stress (for review see (Giordano, 2005, Seddon et al., 2007)). 
ROS are an important mediator of numerous cellular signalling pathways. At low concentrations, 
local, targeted production is crucial for normal functioning of the cell. ROS serve as second 
messengers in response to specific stimuli, such as angiotensin II and endothelin, and modulate 
activity of specific transcription factors altering physiological responses like inflammation. However, 
when ROS are produced in excessive amounts, saturating the cellular antioxidant capacity, they can 
directly react with cellular components. The main pathological effects of oxidative stress are 
 22 
summarized in Figure 4 (Seddon et al., 2007). ROS can damage cellular membranes by lipid 
peroxidation, induce mutagenesis of DNA and damage to chromatin structures and modify activity of 
enzymes critical to normal function of the cell. Also general aging and age-related alterations in the 
cardiovascular system are suggested to be linked to long-term effects of ROS. (Sam et al., 2005, 
Suematsu et al., 2003, Sun et al., 2005, Wenzel et al., 2008, Hemnani and Parihar, 1998, Ide et al., 
2001) 
 
Figure 4. Main pathological effects of increased ROS production. Modified from (Seddon et al., 2007). 
 
ROS have a strong influence in myocardial calcium handling. ROS can target sarcolemmal L-type 
calcium channels and suppress Ca2+ current, inhibit SERCA2 activity and alter the function of cardiac 
sodium channels, potassium channels and ion exchangers, such as Na+/Ca2+ exchanger (NCX) (Guerra 
et al., 1996, Goldhaber, 1996, Kaplan et al., 2003). ROS also has an affect on contractile protein 
machinery; phosphorylation of troponin T via ROS-related kinase apoptosis signal-regulated kinase 1 
(ASK-1) diminishes contractility and impairs calcium handling (He et al., 2003). 
Despite clear preclinical evidence of benefit of preventing ROS-induced cardiac damage, studies 
attempting to treat or prevent this in humans have so far provided disappointing results as ROS-
preventive effect of vitamin supplementations have showed no cardioprotective effects. (Heart 
Protection Study Collaborative Group, 2002, Yusuf et al., 2000) 
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2.1.4.7 Apoptosis 
Apoptosis is an important mechanism during development and elimination of injured or infected cells, 
but in excessive amounts or with longer exposure it can result in failing organ function. In apoptosis, 
cells die in a tightly controlled manner, opposite to cell lysis and inflammatory response in necrotic 
events, representing several molecular characteristics such as cellular and nuclear shrinkage, 
chromatin condensation, cell membrane blebbing, formation of apoptotic bodies and DNA 
fragmentation (for review see (Movassagh and Foo, 2008, van Empel et al., 2005)). 
Apoptosis can be divided into two main categories, the intrinsic pathway, which involves 
mitochondria and endoplasmic reticulum, and the cell membrane death receptor activated extrinsic 
pathway (Movassagh and Foo, 2008, van Empel et al., 2005). The extrinsic pathway is activated via 
binding of death ligands, such as Fas ligand, TNF-α, TNF-related apoptosis inducing ligand (TRAIL) 
or TNF superfamily member 10 (TNFSF10), into their corresponding death receptors. Binding of 
ligand to receptor results in activation of adaptor proteins, recruitment of procaspases 8 and 10 and 
finally formation of death-inducing signalling complex (DISC). In DISC, procaspases 8 and 10 are 
processed via autoproteolysis and released as activated proteases. Activation of apoptosis can result 
directly from activation of the extrinsic pathway or it can be linked to the intrinsic pathway. 
(Movassagh and Foo, 2008, van Empel et al., 2005) 
The intrinsic pathway is promoted via a great variety of stimuli, both extra- and intracellular, such as 
ischaemia/reperfusion, oxidative stress, hypoxia, radiation and DNA damage, resulting in activation 
of death machinery located in the mitochondria and endoplasmic reticulum. One of the main 
characteristics in apoptosis is mitochondrial outer membrane permeabilization. Thus, pro-apoptotic 
factors, located between mitochondrial membranes, are released into the cytoplasm activating the 
irreversible apoptotic pathway. Mitochondrial permeability transition pore, a protein complex in both 
mitochondrial membranes, is considered to mediate the increased permeability of mitochondrial 
membranes and the release of apoptotic mediators, including cytochrome c, second mitochondria-
derived activator of caspase/direct inhibitor of apoptosis-binding protein with low pI 
(Smac/DIABLO), endonuclease G, Omim/Htr and apoptosis-inducing factor (AIF), into cytoplasm. 
Once released into cytoplasm, cytochrome c activates several caspases through “apoptosome” 
formation, Smac/DIABLO binds caspase-inhibitory proteins, and endonuclease G and AIF translocate 
into the nucleus and facilitate DNA damage. (van Empel et al., 2005) 
Mitochondrial outer membrane permeabilization also activates the Bcl-2 family of critical apoptosis 
regulators, which results in release of cytochrome c from the intermembrane space and activation of 
further apoptotic cascades. (van Empel et al., 2005) 
Beside mitochondrial and death receptor pathways, also other possible apoptotic mechanisms exist, 
since mice defective for both caspase 8 (crucial for intrinsic pathway) and 9 (crucial for extrinsic 
pathway) still have apoptosis (Wang and Lenardo, 2000). 
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Heart failure-related increased apoptosis has been demonstrated in both humans and several animal 
models (Narula et al., 1996, Olivetti et al., 1997a, Kang and Izumo, 2000). Although discovered rates 
of on going apoptosis have been low at certain time-point, chronic low-grade apoptosis has been 
shown to result in significant cardiomyocyte loss, which negatively influences the progression of 
heart failure (Abbate et al., 2003, Wencker et al., 2003, Sarkar et al., 2004). For example, in patients 
with dilated cardiomyopathy the prevalence of apoptosis is 0.08-0.25%, approximately 80-250 times 
more than in healthy controls (Saraste et al., 1999, Olivetti et al., 1997b). After myocardial infarction, 
acute rates of apoptosis are even greater, apoptotic rates reaching 2-12% in the border zone of human 
myocardial infarcts (Olivetti et al., 1996, Ottaviani et al., 1999). Of current treatment options for heart 
failure, suppression of effects of angiotensin II or increased β-adrenergic drive by AT1 blockers or β-
blockers, respectively, has been shown to decrease cardiomyocyte apoptosis (Kajstura et al., 1997, 
Groholm et al., 2004, Sabbah et al., 2000), but further pharmacological treatment options are 
required. For example, reduction of oxidative stress via antioxidants, prevention of mitochondrial 
membrane permeabilization, caspase inhibition or ATP-dependent potassium channel openers provide 
exciting possibilities for future treatment options.  
 
2.1.4.8 Dysfunctional energy utilization 
Evidence has emerged of alterations in energy metabolism and mitochondrial functions as a cause and 
effect of heart failure. Proper cardiac functions are strongly related to a balance between energy 
demand and production since the heart has a limited capacity for substrate storage. Development of 
heart failure, regardless of its aetiology, is associated with progressive loss of mitochondrial 
respiratory functions, leading to diminished ATP production capacity. Depressed mitochondrial 
functions and oxidative capacity have been reported in a failing rat heart. (Garnier et al., 2003) Lack 
of energy further hinders the cardiac functions by depressing Ca2+ handling and contractility, leading 
to a vicious cycle of ever-worsening heart failure. 
The human heart requires a constant supply of energy and daily consumption of approximately 30 kg. 
Mitochondrial oxidation of fatty acids and glucose is a major source for ATP in the adult heart. Fatty 
acids are the preferred fuel providing about 70-90% of total ATP. (Huss and Kelly, 2005) 
In the early stages of heart failure, cardiac energy metabolism has foetal-like features;  fatty acid 
utilization remains unchanged or slightly increases with increased glucose utilization with normal 
ATP and decreased phosphocreatine and total creatine levels (for review see (Murray et al., 2007, 
Neubauer, 2007)). In patients with heart failure, a low phosphocreatine/ATP ratio correlates with 
clinical symptoms and predicts mortality with a high accuracy (Neubauer et al., 1997, Conway et al., 
1998). Especially during hypoxia or ischaemia, the utilization of glucose is favoured because it yields 
more ATP per consumed oxygen. However, in the late stages of the disease both fatty acid and 
glucose utilization are diminished, resulting in deleterious energy depletion. Reduced activity of 
mitochondrial creatine kinase and myofibrillar creatine kinase results in loss of high-energy 
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phosphates and ATP impairing both availability and transfer of energy to myofibrils and thus 
provoking diminished inotropic reserve. Increased catecholamine signalling often found in heart 
failure further impairs contractile functions by elevating free ADP concentration. Mitochondrial 
dysfunction is an especially important mechanistic factor in diabetes-related cardiovascular 
complications, where cardiomyocyte energetics is already compromised by increased blood glucose 
and lipid values (for review see (Sack, 2009)). 
Peroxisome proliferators-activated receptor family (PPAR) is a powerful modulator of cardiac 
energetics (for review (Madrazo and Kelly, 2008)). PPARα appears to be the main regulator of 
cardiac lipid metabolism; it controls several genes involved in fatty acid oxidation. Downregulation of 
PPARα, found in hypertrophy of both human and animal hearts, is thought to be the main mechanism 
controlling substrate switch from fatty acid to glucose in the failing heart. Since cellular uptake of 
fatty acids is dependent only on fatty acid plasma level, decreased fatty acid uptake to mitochondria 
leads to accumulation of lipid intermediates and cardiotoxicity. Indeed, PPARα-null mice exhibit 
decreased cardiac fatty acid oxidation rates with increased glucose utilization, cardiac fibrosis and 
decreased contractile reserve (for review, see (Murray et al., 2007, Neubauer, 2007, Madrazo and 
Kelly, 2008)). PPARα is regulated by PPARγ coactivator-1 (also known as PCG-1α), which activates 
also several other genes involved in fatty acid metabolism and oxidative phosphorylation. PCG-1α is 
speculated to be a protective element in the heart since PCG-1α deficient mice exhibit accelerated 
development of heart failure (Arany et al., 2006). 
PPARs and PCG-1α provide an interesting option for modulating cardiac energetics in heart failure, 
but so far data on their exact roles in energy metabolism of the failing heart are controversial. 
However PPARα-agonist fibrates are currently used as a lipid-lowering medication. (Huss and Kelly, 
2005) 
 
2.1.4.9 Cardiomyocyte senescence 
The heart has a limited capability to renew, and because of this cardiac functions and reserve decline 
with age. Ageing myocytes exhibit the following typical pattern of changes (for review see (Bernhard 
and Laufer, 2008)): 
• Reduced ability to cope with stress via reduced expression of heat shock proteins and 
antioxidative defences. 
• Electron leakage and oxidative stress from altered mitochondrial respiratory chain. 
• Reduced excitation/contraction coupling related to down regulation on SERCA2, increased 
expression of cytoskeletal proteins and transcriptional switch of contractile protein isoforms. 
• Shift in the survival signalling balance towards cell death signalling  
Senescent cardiomyocytes show changes in β-adrenergic signalling and angiotensin-signalling 
pathways and eventually loss their ability to compensate cell lose by hypertrophic growth. Finally, 
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aged cardiomyocytes enter an irreversible cell cycle arrest that is characterized by upregulation of 
p16INK4A. (Chimenti et al., 2003, Domenighetti et al., 2005, Urbanek et al., 2003) 
Two products of INK4a/ARF locus, p16INK4A and p19ARF, create a unique system for mediating 
senescence and suppressing malignancy. Despite having a partially shared nucleic acid sequence, they 
are encoded in different reading frames and have neither amino acid homology nor similarity in 
molecular functions (for review, see (Sharpless, 2004, Collado et al., 2007)). Their actions seem to be 
the opposite; p16INK4A has been shown to promote cellular senescence while tumour suppressor 
p19ARF appears to mediate anti-promoting effects on cellular ageing (Baker et al., 2008b). 
Normally, the INK4a/ARF locus is expressed in very low amounts in young tissues, but its expression is 
upregulated in both rodents and human tissues over time (Chkhotua et al., 2003, Krishnamurthy et al., 
2004, Ressler et al., 2006). Increased expression of p16INK4A has also been shown to be involved in 
several cancer diseases, native kidney disease and experimental hypertension (Chimenti et al., 2003, 
Sharpless, 2004, Collado et al., 2007, Westhoff et al., 2008). Human hearts with premature cardiac 
ageing and heart failure show an accumulation of p16INK4a-positive primitive cells and myocytes 
combined with shortened telomeres, representing an imbalance between cellular growth and death 
(Chimenti et al., 2003) and hypertension induced expression of p16INK4A has been suggested to 
mediate tissue damage associated with elevated blood pressure (Bergmann et al., 2008). 
 
2.2 Experimental models of heart failure 
There are several different experimental heart failure models available. These models are ranging 
from naturally occurring heart failure to experimentally or genetically induced disease types. 
Commonly used experimental models of heart failure are presented in Table 1. 
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Table 1. Experimental models used for heart failure. Modified from (Klocke et al., 2007, Monnet and 
Chachques, 2005, Muders and Elsner, 2000). 
Techniques Species Features of heart failure (HF) 
Naturally occurring models   
Cardiomyopathy 
Hamster, dog, 
turkey 
Dilated HF, neurohormonal activation 
Salt-sensitive hypertension Rat Hypertension-induced HF 
Experimentally induced models   
Myocardial ischaemia   
Coronary ligation 
Mouse, rat, dog, 
pig, rabbit 
HF after MI, no confounding atherosclerosis, 
widely used 
Coronary embolism Dog, pig 
HF with acute coronary syndrome or diffuse 
coronary artery disease 
Partial coronary occlusion Dog, pig HF after MI, hibernating myocardium 
Chronic rapid cardiac pacing   
Ventricular pacing Dog, pig, rabbit Low output biventricular HF, reversible  
Pressure overload   
Aortic banding 
Mouse, rat, 
guinea pig 
Diastolic HF with LV hypertrophy, no 
neurohumoral activation  
Monocrotaline Dog, rat, mouse 
Pulmonary hypertension-associated 
hypertrophy of right ventricle 
Volume overload   
Arteriovenous shunt Rat, dog 
Increased LV end-diastolic volume, no 
increased end-diastolic pressure 
Mitral regurgitation Dog Asymmetric LV dilatation 
Aortic regurgitation Rabbit LV dilatation 
Drug-induced heart failure   
Doxorubicin 
Mouse, rat, 
rabbit, dog, pig 
Bilateral ventricular dilatation  
Propranolol 
Mouse, rat, 
turkey 
Acute, stable HF, no ventricular dilatation 
Isoproterenol Rat, mouse 
Catecholamine-induced LV dilatation and 
hypertrophy, widely used 
Genetically modified animals   
Dilated cardiomyopathy 
Mouse, rat, 
hamster 
Large variety of several genetic models for 
different types of HF 
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2.3 Levosimendan 
2.3.1 Mechanism of action 
Levosimendan, the (-) enantiomer of {[4-(1,4,5,6-tetra-hydro-4-metyl-6-oxo-3-
pyridazinyl)phenyl]hydrazono}-propanedinitrile (Figure 5), is a novel inotropic agent used in the 
management of acute decompensated heart failure (for review see (Lehtonen and Poder, 2007)). The 
less active (+) enantiomer is dextrosimendan (Kaheinen et al., 2006). 
 
 
Figure 5. Chemical structure of levosimendan. 
 
Levosimendan increases cardiac contractility by sensitizing the contractile proteins to calcium (Innes 
and Wagstaff, 2003). Levosimendan binds to the calcium-saturated N-terminal domain of troponin C 
in cardiac muscle in a calcium-dependent manner and stabilizes the troponin molecule with 
subsequent prolongation of its effect on the contractile proteins (Innes and Wagstaff, 2003, Haikala et 
al., 1995, Sorsa et al., 2001, Sorsa et al., 2004). Stabilization of the troponin C molecule results in an 
increased amount of actin-myosin interactions, and therefore, increased force for contraction. 
Levosimendan binds to troponin C in a calcium-dependent manner especially, in the beginning of 
systole, and detaches in diastole, increasing the force of contraction without shortening the relaxation 
time or impairing diastolic function. (Haikala et al., 1995) Compared to traditional drugs used for 
acute heart failure, such as dobutamine, levosimendan has one major benefit: it does not elevate 
intracellular calcium concentration (Lancaster and Cook, 1997) and make the heart susceptible to 
arrhythmias. 
Levosimendan has a triple pharmacological mechanism of action; in addition to calcium sensitization, 
it also opens mitochondrial and sarcolemmal ATP-dependent potassium channels (KATP channel) 
(Kopustinskiene et al., 2004, Yokoshiki et al., 1997b). Opening of sarcolemmal KATP channels by 
levosimendan relaxes smooth muscle and dilates all blood vessels such as coronary arteries or 
mesenteric arteries (Bowman et al., 1999, Ozdem et al., 2006). Dilatation of resistance arteries leads 
to decreased systemic resistance, which often can be seen as a transient decrease in blood pressure 
during levosimendan treatment. Dilatation of coronary arteries leads to increased coronary flow, 
which improves tissue perfusion of the heart, preventing ischaemic attacks. Decreased left ventricular 
 29 
filling pressure caused by decreased pre- and afterload also reduce the expression of neurohormones 
and natriuretic peptides. (Parissis et al., 2008) 
Opening of mitochondrial channels has been shown to be involved in ischaemic preconditioning and 
prevention of apoptosis (Wang and Lenardo, 2000, Wakiyama et al., 2002, Ardehali and O'Rourke, 
2005). Levosimendan has been shown to induce pre- and post-conditioning, protect the heart during 
an ischaemic attack, reduce infarct size and decrease apoptosis in a KATP channel –dependent 
manner (du Toit et al., 2008, Kersten et al., 2000). 
Levosimendan is also a selective phosphodiesterase (PDE) 3 inhibitor in vitro, but in clinical doses 
the relevance of PDE inhibition is considered to be somewhat insignificant (Kaheinen et al., 2006, 
Ajiro et al., 2002, Szilagyi et al., 2005). 
 
2.3.2 Pharmacokinetics of levosimendan 
Levosimendan shows a linear pharmacokinetic in a therapeutic dose of 0.05-0.2 µg/kg/min. It has a 
volume of distribution of 0.2 l/kg. Levosimendan binds strongly (97-98%) to plasma proteins, mainly 
albumin, and has a clearance of 3.0 ml/min/kg. (Antila et al., 2007) 
Levosimendan is rapidly metabolized, with elimination half-life of approximately 1 h; only small 
proportion (less than 0,05%) of the levosimendan dose is excreted unmetabolized in urine. 
Levosimendan is mainly excreted as metabolites, in urine (54%) and faeces (44%). (Antila et al., 
2007) About 5% of the total dose of levosimendan is secreted into the small intestine where it is 
reduced by the internal bacteria to OR-1855 (R)-6-(4-Amino-phenyl)-5-methyl-4,5-dihydro-2H-
pyridazin-3-one), which is further metabolized with N-acetyltransferase 2 to biologically active OR-
1896 (N-[4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl]acetamide). 
 
2.3.3 Pharmacodynamics of levosimendan 
Levosimendan dose dependently increases force of contraction in cardiac muscle without impairing 
relaxation of ventricles. It also dilates systemic and coronary resistance arteries and systemic 
capacitance veins. Levosimendan infusion increases cardiac output, stroke volume, ejection fraction 
and pulse rate, and decreases systolic and diastolic blood pressure, pulmonary wedge pressure, 
pressure in the right atrium and systemic resistance. (De Luca et al., 2006) 
 
2.3.3.1 Clinical use of levosimendan 
Levosimendan is used for hospitalized treatment of acute heart failure when standard treatment fails 
to provide a sufficient inotropic effect. It is administered parenterally via the peripheral or central vein 
as a single 24-h infusion based on individual characteristics of the patient, e.g. other inotropic or 
vasodilating drugs. 
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Levosimendan infusion is generally started with a bolus, 6-12 µg/kg over 10 minutes, and infusion is 
continued at a dose of 0.1 µg/kg/min. Haemodynamic response is monitored carefully to evaluate 
appropriate dosing, and the infusion dose is set between 0.05-0.2 µg/kg/min. Due to possible 
accumulation of the active, long-lived metabolite of levosimendan, OR-1896, levosimendan infusion 
should not be continued beyond of 24 h, however positive haemodynamic effects can be seen as long 
as 9 days after infusion. (Archan and Toller, 2008) Preliminary data indicate the safety and efficacy of 
repeated levosimendan infusions, but further studies are warranted to evaluate continuous or repeated 
levosimendan administration (Parle et al., 2008, Parissis et al., 2006b, Nanas et al., 2005). 
Contraindications include possible allergies to levosimendan or auxiliary substances of the product, 
severe hypotension and tachycardia, severe renal (creatinine clearance <30 ml/min) or hepatic failure 
and a previous episode of torsades de pointes tachycardia. Levosimendan has been found to be 
teratogenic in animal experiments, and it should be used during pregnancy only when the maternal 
benefit exceeds the potential harm to the foetus. The effect of levosimendan on lactation remains 
unknown in humans. In rats, levosimendan is excreted in milk, and therefore women receiving 
levosimendan probably should not breastfeed. 
In heart failure patients, levosimendan has a positive inotropic and vasodilatory effect, which leads to 
increased cardiac contraction force and perfusion of cardiac muscle and decreased pre- and afterload 
without impaired diastolic function (for review see (Kasikcioglu and Cam, 2006)). With patients 
recovering from cardiac surgery or procedure, such as balloon angioplasty, or patients treated with 
thrombolytic therapy, levosimendan activates the stunned myocardium and increases coronary flow 
(Zangrillo et al., 2009). Levosimendan infusion increases neither cardiac oxygen demand nor 
intracellular calcium concentration, while plasma concentrations of natriuretic peptides and 
endothelin-1 significantly decrease. Levosimendan does not elevate plasma catecholamine 
concentration with therapeutic dosing. (Antila et al., 2007) 
Limited amount of data are available on the cost efficacy of levosimendan in treating heart failure. 
Levosimendan is more expensive than dobutamine, but the overall costs of levosimendan appear to be 
lower or comparable with those of placebo or dobutamine due to a shorter in-hospital time (Oliveira et 
al., 2005, Cleland et al., 2004, de Lissovoy et al., 2009). 
 
2.3.3.2 Adverse effects 
Levosimendan is generally well tolerated. The clinically most relevant adverse events are mainly 
originated by hypotension and arrhythmias. (Table 2) 
 31 
Table 2 Adverse effects related to clinical use of levosimendan. “Common” indicates adverse effect in 1 of 100 
patients, “very common” 1 of 10 patients. (Fimea, 2009) 
Organ system Prevalence Adverse effect 
Metabolic and nutritional disorders Common  Hypokalemia 
Psychic disorders Common  Insomnia 
Nervous system Very common Headache 
 Common  Vertigo 
Heart Very common Tachycardia 
 Common  Atrial fibrillation 
Tachycardia 
Heart failure 
Cardiac ischaemia 
Extra systole 
Vasculature Very common Hypotension 
Gastrointestinal-track Common Nausea 
Constipation 
Diarrhoea 
Vomiting 
Laboratory markers Common Decrease in blood haemoglobin 
 
2.3.3.3 Clinical studies on levosimendan 
Intravenous levosimendan has been assessed in several medium- and large-scale clinical studies of 
treatment of heart failure (Table 3). Levosimendan treatment improves symptoms of heart failure, 
such as dyspnoea or fatigue and plasma BNP, relative to placebo (Packer, 2005, Slawsky et al., 2000). 
Compared with dobutamine, levosimendan improves symptoms equally or slightly better and is 
associated with a shorter hospital stay (Packer, 2005). 
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Levosimendan reduced mortality in the LIDO (Efficacy and safety of intravenous levosimendan 
compared with dobutamine in severe low-output heart failure), RUSSLAN (Safety and efficacy of a 
novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute 
myocardial infarction. A randomized, placebo-controlled, double-blind study) and CASINO (Calcium 
Sensitizer or Inotrope or None in Low Output Heart Failure) trials, and a positive effect on mortality 
was still seen at 6 months after the infusion (Follath et al., 2002, Moiseyev et al., 2002, Zairis et al., 
2004). In REVIVE (The Randomized multicenter EValuation of Intravenous leVosimendan Efficacy 
vs. placebo in the short-term treatment of decompensated heart failure) trials, levosimendan was 
associated with a slightly higher mortality than placebo, but this difference was not statistically 
significant (Packer, 2005). However, it is noteworthy that neither the LIDO, RUSSLAN, CASINO, 
nor REVIVE trials were powered for assessment of mortality, and therefore, any conclusions on a 
matter should be drawn with care. In the larger SURVIVE (Survival of Patients With Acute Heart 
Failure in Need of Intravenous Inotropic Support) trial (total of 1327 patients), levosimendan and 
dobutamine showed similar results for mortality at any time-point or comparisons between treatments 
(Mebazaa et al., 2007). In conclusion, data on levosimendan in the short- or long-term survival of 
patients with acute decompensated heart failure remain inconclusive. 
Levosimendan has also been investigated extensively in smaller scale clinical studies. Heart failure is 
associated with changes in inflammatory functions, oxidative stress and induction of apoptosis, which 
all of worsen survival (for review see (Giordano, 2005, Huss and Kelly, 2005, Foo et al., 2005)). 
Levosimendan infusion has been shown to reduce markers of oxidative and nitrosative stress and 
inflammatory and apoptotic pathways in patients with advanced heart failure without severe adverse 
effects (Adamopoulos et al., 2006b, Avgeropoulou et al., 2005, Parissis et al., 2004b, Parissis et al., 
2007, Trikas et al., 2006). Levosimendan is also speculated to beneficially affect extracellular matrix 
remodelling based on the finding that levosimendan reduces serum levels of matrix 
metalloproteinases in patients with decompensated heart failure (Tziakas et al., 2005). The use of 
levosimendan has been evaluated in several diseases other than heart failure, and it has been shown to 
have beneficial effects after aortic valve replacement for aortic stenosis and on refractory cardiogenic 
shock, renal functions on heart failure, acute respiratory distress syndrome and pulmonary failure and 
stunned myocardium (Sonntag et al., 2004, Yilmaz et al., 2007, Morelli et al., 2006, Jorgensen et al., 
2008, Fuhrmann et al., 2008). Levosimendan administered in a preconditioning manner before 
coronary artery bypass grafting protects from myocardial damage induced by the procedure; this 
finding may be related to levosimendan ion channel opening properties (Tritapepe et al., 2006). 
To summarize, results from levosimendan trials suggest that levosimendan improves symptoms and 
clinical course compared with placebo and is similar to dobutamine. According to a very recent meta-
analysis, levosimendan has a positive trend towards improved survival relative to placebo. Compared 
with dobutamine, levosimendan is associated with improved survival. (Delaney et al., 2008) 
Levosimendan has also been shown to have additional beneficial effects on inflammation markers and 
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apoptosis (Adamopoulos et al., 2006b, Parissis et al., 2004b, Trikas et al., 2006), but the true clinical 
relevance of these findings is a subject for future research.  
 
2.3.3.4 Clinical studies on oral levosimendan 
Data on oral use of levosimendan remain limited. Oral levosimendan has been shown to improve 
cardiac function in dogs with heart failure and to prevent mortality in rats with coronary occlusion 
(Masutani et al., 2008, Lepran and Papp, 2003). In patients with heart failure oral levosimendan has 
been shown to induce a similar inotropic effect as the intravenously administered form (Poder et al., 
2003). A very recent study of oral levosimendan in patients with severe chronic heart failure patients 
(PERSIST) failed to show a significant improvement in cardiac functions. However, patients in 
PERSIST did have a reduction in BNP values and improved self-reported quality of life. (Nieminen et 
al., 2008) 
 
2.3.3.5 Experimental studies on levosimendan 
Experimental studies on different animal models, including the rat (Boost et al., 2008, Louhelainen et 
al., 2007), sheep (Dubin et al., 2006, Dubin et al., 2007), guinea pig (Brendt et al., 2008), dog (Papp 
et al., 2006) and pig (Cunha-Goncalves et al., 2007, Koudouna et al., 2007, Kerbaul et al., 2007), 
have revealed a marked role of levosimendan in treating various diseases models. Levosimendan has 
been shown to reduce inflammatory response and mortality after experimental lung injury and chronic 
hypertension (Boost et al., 2008, Louhelainen et al., 2007), to improve outcome of cardiopulmonary 
resuscitation after cardiac arrest (Koudouna et al., 2007) and to restore right ventricular failure due to 
pulmonary embolism (Kerbaul et al., 2007). Reports on levosimendan in management of 
endotoxaemia are somewhat conflicting, and beneficial effects, such as improved renal function or 
prevention of intramucosal acidosis, might be overshadowed by episodes of systemic hypotension or 
ischaemia (Dubin et al., 2006, Cunha-Goncalves et al., 2007, Zager et al., 2006). In cells exposed to 
inflammatory stimuli, levosimendan decreases nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-κB)-mediated transcription, inducible nitric oxide synthase (iNOS) expression and NO 
production (Sareila et al., 2008). 
Levosimendan provides an interesting option for treatment of nerve injuries. In models of spinal cord 
damage by aorta clamping, administration of levosimendan has reduced ischaemic damage and 
provided a better neurological outcome (Katircioglu et al., 2008, Lafci et al., 2008). 
Ischaemic preconditioning prior to ischaemia-reperfusion injury is known to protect cardiac muscle 
and reduce size of infarction. Levosimendan is, besides its mainly recognized role as a calcium 
sensitizer, also an opener of both sarcolemmal and mitochondrial KATP channels without elevation of 
Ca2+ currents in both humans and experimental animal models (Kopustinskiene et al., 2004, 
Yokoshiki et al., 1997b, Hohn et al., 2004, Kaheinen et al., 2001, Kopustinskiene et al., 2001, Usta et 
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al., 2006, Yokoshiki et al., 1997a). Pretreatment with levosimendan and ischaemic preconditioning 
improve survival and offer cardioprotection in a similar manner (Kersten et al., 2000, Das and Sarkar, 
2007). These cardioprotective effects are speculated to be mediated via both opening of mitochondrial 
KATP channels and NO –dependent pathways since vasodilatory and preconditioning effects can be 
abolished with potassium channel antagonists (Kopustinskiene et al., 2001, Das and Sarkar, 2007). 
Anti-apoptotic effects of levosimendan, discovered in a hypertensive rat model (Dahl/Rapp SS rat), 
are also speculated to be mediated via its blood pressure-independent potassium channel opening 
properties (Louhelainen et al., 2007). 
 
2.3.4 The active metabolite OR-1896 
Levosimendan has two active circulating metabolites, OR-1896 and OR-1855, both found in humans 
and rats (Koskinen et al., 2008). The active metabolite OR-1896 has similar haemodynamic functions 
as the parent drug, while OR-1855 unable to produce any haemodynamic effects (Segreti et al., 2008, 
Takahashi et al., 2000b, Takahashi et al., 2000a, Banfor et al., 2008). OR-1896 has a considerably 
longer half-life than levosimendan, approximately 80 h vs. 1 h in humans and 6.5 h vs. 0.76 h in rats 
(Orion Pharma, unpublished data), making it responsible for long-term - up to one week - effects of a 
single levosimendan infusion (Kivikko et al., 2003, Lilleberg et al., 2007, Puttonen et al., 2008). OR-
1896 is also less bound to plasma proteins than levosimendan, approximately 40% vs 97%, which 
could explain its greater effects (Antila et al., 2004a). 
The steady-state equilibrium of metabolites of levosimendan differs based on the genetic 
polymorphism of the metabolizing enzyme, N-acetyltransferase. In slow acetylators, the dominant 
metabolite is OR-1855, whereas rapid acetylators have more OR-1896 in their system. Asian patients 
tend to be fast acetylators (70-80%) and Caucasians slow acetylators (40-70%). (Parissis et al., 2008) 
Rapid acetylators show 3.5 times higher plasma OR-1896 concentration than slow acetylators with 
similar levosimendan dosing. However, this polymorphism does not seem to impair haemodynamic 
responses in the therapeutic dose range. (Antila et al., 2004b) 
 
2.3.4.1 Mechanism of action of OR-1896 
Although studied to a lesser extent than levosimendan, OR-1896 has been shown to have similar 
pharmacological actions. As a parent compound, OR-1896 also exhibits calcium-sensitizing 
properties, and its effects are mediated via increased contractility without elevated levels of 
intracellular calcium or impaired relaxation. (Takahashi et al., 2000b, Takahashi et al., 2000a, Papp et 
al., 2004, Szilagyi et al., 2004, Takahashi and Endoh, 2002) OR-1896 also induces arterial 
vasodilatation by activating potassium channels (Segreti et al., 2008, Banfor et al., 2008, Erdei et al., 
2006). Despite OR-1896 having weak PDE inhibiting-properties, it is believed to function through the 
mechanisms of calcium sensitization and potassium channel opening (Szilagyi et al., 2004). 
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3 Aims of the study 
 
The aim of this study was to investigate the cardiovascular effects of oral calcium sensitizers 
levosimendan and OR-1896 in two different experimental models of heart failure, namely 
hypertension-induced heart failure with preserved systolic function and experimental myocardial 
infarction induced by coronary ligation leading to post-infarct heart failure with decreased systolic 
function. Furthermore, the molecular mechanisms of cardiac remodelling associated with heart failure 
were investigated. 
 
Specific objectives were the following: 
 
I. To investigate whether oral treatment with calcium sensitizer levosimendan could prevent 
excess cardiovascular mortality and hypertension-induced cardiac remodelling in 
Dahl/Rapp SS rats on a high-salt diet. The possible mechanisms of action mediating the 
beneficial effects of oral levosimendan were also examined. 
II. To evaluate whether OR-1896, the active metabolite of levosimendan, could also prevent 
excess cardiovascular mortality and hypertension-induced cardiac damage in Dahl/Rapp 
SS rats on a high-salt diet. 
III. To assess whether oral levosimendan treatment could prevent post-infarct heart failure 
and cardiac remodelling in spontaneously diabetic Goto-Kakizaki rats as well as in non-
diabetic Wistar rats. The influence of oral levosimendan treatment on cardiomyocyte 
hypertrophy, cardiomyocyte apoptotic signalling, inflammatory response, cardiac 
oxidative stress and fibrosis and myocardial expression of calcium-handling proteins was 
also examined.  
IV. To investigate the cardiovascular effects of oral OR-1896 treatment on post-infarct heart 
failure and cardiac remodelling in spontaneously diabetic Goto-Kakizaki rats. 
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4 Materials and methods 
4.1 Experimental models and animal welfare 
4.1.1 Dahl/Rapp salt sensitive (SS) rat 
The inbred salt-sensitive Dahl/Rapp salt sensitive (SS) rat is a model of salt-induced hypertension 
with severe target organ damage, including cardiac hypertrophy leading to congestive heart failure, 
vascular damage and renal failure with relatively preserved ejection fraction (Klotz et al., 2006, Rapp 
and Dene, 1985, Walder et al., 1996). The model mimics well the hypertension-induced cardiac 
hypertrophy and heart failure found in humans. 
When kept on high-salt (6%) diet, Dahl/Rapp SS rats rapidly develop fulminant hypertension with 
increased mortality visible already 3 weeks into the diet. The overall mortality is almost 100% after 8 
weeks on the high-salt diet.  
Development of hypertensive heart disease in Dahl/Rapp SS rats has been shown to involve several 
different mechanisms. Alterations in neurohumoral and natriuretic activation and increased apoptosis 
all play major roles in the development of heart failure. Dahl/Rapp SS rats exhibit salt induced 
abnormal expression of calcium-handling proteins, especially a decrease in SERCA2 expression and 
an imbalance in the SERCA2 to NCX ratio or the SERCA2 to PLN ratio. Desensitization to calcium 
has been demonstrated to be related to transition to heart failure; Dahl/Rapp SS rats have a defect in 
the thin filament system making them susceptible to calcium insensitivity (Yoneda et al., 2001, Seki 
et al., 2003b, Kihara and Sasayama, 1997, Noguchi et al., 2003). Moreover, the inability to increase 
production of vasorelaxant NO, with its need increasing with elevating blood pressure, damages the 
heart muscle similarly as seen in hypertensive nephrosclerosis (Chen et al., 1993). 
 
4.1.2 Diabetic Goto Kakizaki (GK) rat 
The Goto Kakizaki (GK) rat, developed by selective breeding of glucose-intolerant Wistar rats, is a 
spontaneous, non-obese and normotensive model of type 2 diabetes exhibiting very similar metabolic, 
hormonal and vascular features to type 2 diabetes found in humans (Goto et al., 1976). GK rats 
develop mild hyperglycaemia (1.5 to 2 times normal) and hyperinsulinaemia, glucose intolerance with 
impaired glucose-induced insulin secretion and peripheral insulin resistance. GK rats also exhibit 
slight differences in blood lipids, renal damage, cardiac hypertrophy and hypoxia-inducible cardiac 
dysfunction (Schrijvers et al., 2004, Bisbis et al., 1993, Gauguier et al., 1996, Kristiansen et al., 2004, 
El-Omar et al., 2004). Hypertension, albuminuria, cardiac hypertrophy and impaired endothelin-
dependent relaxation can be further induced on Goto-Kakizaki rat by adding salt (6%) to the diet. 
Increased functions of the RAS system plays a major role in development of diabetes induced tissue 
damage in the GK rat since treatment with drugs affecting to RAS system is able to prevent or 
alleviate end-organ damage. (Cheng et al., 2001) Heart failure can be induced to GK rat with 
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experimental infarction. The Wistar rat, genetic basis for the GK rat, is used as normoglycemic 
control for the GK rat. 
 
4.1.3 Animal welfare 
This investigation conforms to the guide for the care and use of laboratory animals published by the 
US National Institutes of Health (NIH Publication No. 85-23, revised 1996). The protocols were 
approved by the Animal Experimentation Committee of the University of Helsinki, Finland, and the 
Provincial State Office of Southern Finland. 
Animals were purchased from M&B, Denmark (GK rat) or Harlan, USA (Dahl/Rapp SS rat and 
Wistar rat). The rats had free access to standard chow (Harlan, Eystrup, Germany) and drinking water. 
High salt diet was produced by adding NaCl (Honeywell Riedel-de-Haen, Hanover, Germany) to 
commercial low salt diet (Na 0.3 %, K 0.8 %, Mg 0.2 %; Harlan). 
 
4.2 Study design 
The study design, including animal model, experimental procedure, treatment and dosing, and follow-
up time are seen in tables 4-6. 
 
Table 4 Study designs for Studies I and II. FU denotes follow-up. 
Study I     
Groups Rat strain Salt in food Oral levosimendan 
dosage  
FU, 
weeks 
DAHL HS Dahl/Rapp SS  High, 6 % - 7 
DAHL HS + levo high Dahl/Rapp SS  High, 6 %  3 mg/kg 7 
DAHL HS + levo low Dahl/Rapp SS  High, 6 % 0.3 mg/kg 7 
DAHL LS Dahl/Rapp SS  Normal - 7 
     
Study II     
Groups Rat strain Salt in food Oral OR-1896 dosage FU, 
weeks 
DAHL HS Dahl/Rapp SS  High, 6 % - 7 
DAHL HS + OR-1896 high Dahl/Rapp SS  High, 6 % 0.2 mg/kg 7 
DAHL HS + OR-1896 low Dahl/Rapp SS  High, 6 % 0.02 mg/kg 7 
DAHL LS Dahl/Rapp SS  Normal - 7 
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Table 5 Study design for Study III 
 
Table 6 Study design for Study IV 
 
4.3 Experimental myocardial infarction 
Experimental myocardial infarction was induced the left anterior descending coronary artery (LAD) 
ligation in male eight-week-old spontaneously diabetic GK rat and non-diabetic Wistar rats as 
described previously (Palojoki et al., 2001) under ketamine (65 mg/kg, i.p.) and medetomidine (0.5 
mg/kg, i.p.) anaesthesia. Long-acting insulin (1 IU/rat) was given two hours before anaesthesia to GK 
rats to prevent hyperglycemia. Buprenorphine (0.02 mg/kg s.c.), given twice a day for two 
consecutive days, was used as post-operative analgesia. 24 hours after surgery surviving rats were 
randomized into study groups (tables 4 and 5). 
 
4.4 Levosimendan and OR-1896 dosage 
Levosimendan (10 mg/l) and OR-1896 (0,5 mg/l) (Orion Pharma, Espoo, Finland) were given orally 
via drinking fluid to produce a daily dose of approximately 0.3-3 mg/kg and 0.02-0.4 mg/kg, 
respectively. The levosimendan and OR-1896 dosages were chosen based on our previous 
experiments (Louhelainen et al., 2007, Levijoki et al., 2001, Louhelainen et al., 2009). In these 
Study III     
Groups Rat strain MI Oral levosimendan 
dosage 
FU, weeks 
GK MI Goto Kakizaki  X - 12 
GK MI + levo Goto Kakizaki  X 1 mg/kg 12 
GK SHAM Goto Kakizaki - - 12 
GK SHAM + levo Goto Kakizaki - 1 mg/kg 12 
WIS MI Wistar X - 12 
WIS MI + levo Wistar X 1 mg/kg 12 
WIS SHAM Wistar - - 12 
WIS SHAM + levo Wistar - 1 mg/kg 12 
Study IV     
Rat strain Rat strain MI Oral OR-1896 dosage  FU, weeks 
GK MI, 1w Goto Kakizaki X - 1 
GK SHAM, 1w Goto Kakizaki - - 1 
GK MI, 4w Goto Kakizaki X - 4 
GK MI + OR-1896, 4w Goto Kakizaki X 0.4 mg/kg 4 
GK SHAM, 4w Goto Kakizaki - - 4 
GK SHAM + OR-1896, 4w Goto Kakizaki  - 0.4 mg/kg 4 
GK MI, 12w Goto Kakizaki X - 12 
GK MI + OR-1896, 12w Goto Kakizaki X 0.4 mg/kg 12 
GK SHAM, 12w Goto Kakizaki - - 12 
GK SHAM + OR-1896, 12w Goto Kakizaki  - 0.4 mg/kg 12 
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studies, the levosimendan and OR-1896 dosage used here exerted a significant therapeutic effect and 
produced a clinically relevant plasma drug concentration (Kivikko et al., 2002b). Fresh levosimendan 
and OR-1896 solutions were prepared daily. 
 
4.5 Blood pressure measurement and sample preparation 
Systolic blood pressure was measured using a tail-cuff blood pressure analyzer (Apollo-2AB Blood 
Pressure Analyzer, Model 179-2AB, IITC Life Science, Woodland Hills, CA, USA). Urine samples 
were collected in one or two consecutive 24-h periods in metabolic cages. Rats were anaesthetized 
with CO2/O2 (AGA, Riihimäki, Finland) and decapitated. Blood samples were collected for using 
ethylenediaminetetra-acetic acid (EDTA) as an anticoagulant. The hearts were excised, washed with 
ice-cold saline, blotted dry, weighed and snap-frozen in liquid nitrogen or isopentane (-35°C). All 
samples were stored at -80°C until assayed. 
 
4.6 Echocardiography 
Transthoracic echocardiography (Toshiba Ultrasound, Tokyo, Japan) was performed on all rats under 
isoflurane anaesthesia (AGA, Riihimäki, Finland) in a blinded fashion. Parameters needed for the 
calculation of cardiac function and cardiac dimensions were measured from three systole-diastole 
cycles. A short-axis view of the left ventricle at the level of the papillary muscles was obtained by a 
two-dimensional imaging method (Gibson method), using a 15-MHz linear transducer. Two-
dimensionally guided M-mode recording through the anterior and posterior walls of the left ventricle 
was used to measure the left ventricle (LV) end-systolic (LVESD), and end-diastolic (LVEDD) 
dimensions. Also interventricular septum (IVS) and posterior wall (PW) thickness were measured. LV 
fractional shortening (FS) and ejection fraction (EF), were calculated from the M-mode LV 
dimensions using the following equations:  
FS (%) = {(LVEDD-LVESD) / LVEDD} x 100 
EF = SV / EDV 
SV = EDV – ESV 
EDV = 0.52 x (0.98 x (LVIDD/10) + 5.90) x (LVIDD/10)2 
ESV = 0.52 x (1.14 x (LVIDS/10) + 4.18) x (LVIDS/10)2 
LVIDD = Diameter of the short-axis left ventricle in end diastole. LVIDS = Diameter of the short-
axis left ventricle in end systole. Cardiac output (CO) was calculated from heart rate (HR) and stroke 
volume (SV=LVEDV-LVESV), CO = HR x SV. 
 
4.7 Infarct size, collagen volume fraction and cardiomyocyte cross-sectional area 
The hearts were fixed in 10% buffered formalin solution for histological analysis. Transversal 5-µm-
thick sections of the paraffin-embedded left ventricle were cut and stained with Masson’s trichrome or 
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picrosirius red. The infarct sizes were determined planimetrically from the trichrome-stained 
histological sections as described elsewhere (Palojoki et al., 2001, Pfeffer et al., 1979). Remote area 
interstitial collagen volume fraction was measured from picrosirius red-stained histological sections 
by light microscopy (x200) using computerized software (ImageJ, NIH). Cardiomyocyte cross-
sectional area was measured by conventional light microscopy at x400 magnification as described 
previously (Vahtola et al., 2008). 
 
4.8 Myocardial morphology 
Histology of the myocardial samples was evaluated with conventional light microscopy. The severity 
of observed lesions was graded with numerical values characterizing the degree of damage on a whole 
tissue level as follows: “0, no abnormalities detected; 1, minimal; 2, mild; 3, moderate; 4, marked; or 
5, severe”. Severity grading was performed on the coronary arteries and the myocardium. (Herbert et 
al., 2002) 
 
4.9 Immunohistochemistry 
Immunoperoxidase staining for p16INK4a was performed using 5-µm frozen sections with 1:100 diluted 
primary monoclonal p16INK4a antibody (Santa Cruz Biotechnologies, Santa Cruz, CA, USA) and 
peroxidase-conjugated rabbit anti-mouse secondary antibody (DAKO A/S, Glostrup, Denmark). 3-
amino-9-ethylcarbazole, was added to yield a red reaction product, and finally, the sections were 
slightly counterstained with Mayer’s hemalaun (Merck, Whitehouse, NJ, USA), blued in tap water. 
Perivascular monocyte/macrophage infiltration was examined by immunohistochemistry using rat 
ED-1 (Serotec Ltd., Oslo, Norway) as a primary antibody. Cardiac nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase expression was assessed using p47phox (BD Biosciences, Pharmingen, 
USA) as primary a antibody. 
Heart paraffin sections were deparaffinized and nonspecific antibody binding was blocked with 1% 
bovine serum albumin and 10% goat serum in phosphate buffered saline. The sections were incubated 
with polyclonal C-kit antibody (Santa Cruz Biotechnologies inc., Santa Cruz, CA, USA) at dilution 
1:100 for overnight at +4°C. After washing, the sections were incubated with secondary biotin-
conjugated antibody for 1 h at room temperature, and avidin biotin enzyme reagent (Vector 
Laboratories, Burlingame, CA, USA) was used. The sections were counterstained with hematoxylin 
before being examined under a light microscope. 
 
4.10 TUNEL apoptosis assay 
Cardiomyocyte apoptosis was assessed by the terminal deoxynucleotidyl transferase mediated dUTP 
nick end labelling (TUNEL) assay. Nuclear DNA strand breaks were end-labelled with digoxigenin-
conjugated dideoxy-UTP by terminal transferase and visualized immunohistochemically with alkaline 
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phosphatate-conjugated digoxigenin antibody. Adjacent tissue sections treated with DNase I to induce 
DNA fragmentation were used as a positive control for apoptosis. The percentages of TUNEL-
positive cardiomyocytes were calculated using light microscopy (X 200 magnification) with an ocular 
grid. (Palojoki et al., 2001, Kyto et al., 2004) 
 
4.11 Apoptosis microarray 
RNA from hearts (n=4-5 in each group) was extracted with Trizol (Gibco, Invitrogen Co., Carlsbad, 
CA, USA) and purified with RNeasy mini kit (Qiagen N.V., Venlo, The Netherlands). RNA was 
reverse-transcribed to cDNA and back to cRNA for microarray analysis using the Oligo GEArray for 
Rat Apoptosis (Superarray, Frederick, MD, USA) containing 114 known, apoptosis-related genes. 
Samples were hybridized to separate GEArray plates overnight in a hybridization oven (Stratagene 
Personal Hyb, La Jolla, CA, USA) and scanned (Packard Biosciences ScanArray 4000, Boston, MA, 
USA). Data extraction and analysis were performed with the GEArray Expression Analysis Suite 
software (Superarray, Bethesda, MD, USA). Significant differences in apoptotic microarrays were 
tested with Student’s t-test. 
 
4.12 Western blotting 
Samples from left ventricle were homogenized and the proteins were isolated with Micro BCA 
Protein Assay kit (Thermo scientific, Rockford, IL, USA). Myocardial samples were 
electrophoretically separated by 8% SDS-PAGE (15 µg total protein per lane). Proteins were 
transferred to a PVDF membrane (Immobilon-P®, Millipore, Bedford, MA, USA), and the 
membranes were probed with the following dilutions of primary antibodies; rabbit anti-NCX, 1:5000 
(Alpha Diagnostics, San Antonio, TX, USA), rabbit anti-Serca2, 1:5000 (Abcam, Cambridge, 
England). Tubulin was used as a loading control (Anti-alpha tubulin, Abcam). Horseradish 
peroxidase-conjugated anti-rabbit secondary antibody (Chemicon, Temecula, CA, USA) was 
subjected to enhanced chemiluminescence solution (GE Healthcare, Uppsala, Sweden) and exposed to 
x-ray film (Hyperfilm-ECL, GE Healthcare). The relative protein expression was quantified from the 
x-ray film by densitometry (Genesnap, Synoptics, Cambridge, UK). 
 
4.13 Electrophoretic mobility shift assay of nuclear FOXO3a transcription factor 
Electrophoretic mobility shift assay (EMSA) was used to determine the quantity of DNA-binding 
FOXO3a transcription factor from cardiac left ventricular nuclear extracts. Nuclear proteins were 
extracted by grinding in liquid nitrogen and incubating in a buffer with protease inhibitor, membrane 
proteins were solubilized with Nonidet P-40 (Roche Diagnostics GmBH, Mannheim, Germany). 5 µg 
of nuclear extracts were incubated with the following digoxigenin-tagged FOXO3a oligonucleotides: 
5´-DIG-ATT GCT AGC AAG CAA AAC AAA CCG CTA GCT TA-3´and 5´-DIG-TAA GCT AGC 
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GGT TTG TTT TGC TTG CTA GCA AT-3´ (Oligomer, Helsinki, Finland). Nuclear proteins were 
separated by 5% SDS-PAGE, blotted to a nylon membrane (Hoefer semiPhor, TE77, Amersham 
Biosciences, Buckinghamshire, UK) and cross-linked to the membrane. The membrane was probed 
with rabbit anti-digoxigenin-AP-conjugate (Roche Diagnostics GmBH), incubated in detection 
reagent (CDP Star, Roche Diacnostics GmBH) and exposed to an x-ray film (Kodak Inc., Japan). The 
indication reaction was done by incubating the samples with tagged and untagged oligonucleotides 
and probing with rabbit anti-forkhead (Drosophila) homolog (rhabdomyosarcoma) like 1 (FKHRL1) 
(sc-11351, Santa Cruz, CA, USA). Proteins extracted from HeLa-cells was used as positive and water 
as negative control. 
 
4.14 Quantitative real-time RT-PCR 
Total RNA from rat hearts was collected with Trizol® (Gibco, Invitrogen, Carlsbad, CA, USA). 1 µg 
of isolated RNA was treated with DNAse 1 (Deoxyribonuclease 1, Sigma Chemicals Co., St Louis, 
MO, USA) and reverse transcribed to cDNA by RT enzyme (Enhanced avian Hot Start RT-PCR kit, 
Sigma Chemicals Co or Im-Prom-II RT system, Promega, Madison, WI, USA). One µl of cDNA was 
subjected to quantitative real-time RT-PCR using the Lightcycler® instrument (Roche Diagnostics, 
Neuilly sur Seine, France) for detection of ANP, BNP, connective tissue growth factor (CTGF), 
interleukin-6 (IL-6), atrogin-1, Bim (BCL2L11), tumour necrosis factor receptor superfamily member 
12a (Tnfrsf12a), p16INK4A, p19ARF, vascular endothelial growth factor (VEGF), nuclear receptor 4a3 
(NR4a3), monocyte chemoattractant protein 1 (MCP-1), transcription factor 5 (E2F-5), PPARγ 
coactivator-1α (PCG-1α), transcription factor A, mitochondria (TFAM), nuclear respiratory factor 1 
(NRF-1), SERCA2, NCX, osteopontin, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and 
ribosomal 18S mRNA. Primer sequences are presented in table 7. The samples were amplified using 
FastStart DNA Master SYBR Green 1 (Roche Diagnostics) according manufacturer’s protocol. The 
quantities of the PCR products were quantified with an external standard curve amplified from 
purified PCR product. 
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Table 7. RT-PCR primer sequences. 
 Forward primer Reverse Primer Reference 
18S ACATCCAAGGAAGGCAG
CAG 
TTTTCGTCACTACCTCCCCG (Wellner et 
al., 2005) 
GAPDH GGATGCAGGGATGATGT
TCT 
GAAGGGCTCATGACCACAGT (Farjah et 
al., 2003) 
ANP CCGATAGATTCTGCCCTC
TTGAA 
CCCGAAGCAGCTTGATCTTC (Heyen et 
al., 2002) 
BNP AACTTCTAAAAAGACTC
CTTAGGTCTCAA 
GCCATCTTGCAATTTCGAAGTC (Nagata et 
al., 2002) 
IL-6 AGGAAGGCAGTGTCACT
CATTGT 
CTTGGGTCCTCATCCTGGAA (Heyen et 
al., 2002) 
CTGF GGCAGGGCCAACCACTG
TGC 
CAGTGCACTTGCCTGGATGG - 
Atrogin-1 CACGATCACCGACCTG AGATCAATCGCTTGCGGA - 
Tnfrsf12a CGCGGACCTCGACAAG CTTTTCTCTCCGGCGGA - 
Bim CTTCCGCCTCTCGGTAAT CGGCACCCATGAGTTG - 
p16INK4a AACACTTTCGGTCGTACC
C 
GTCCTCGCAGTTCGAATC (Bastide et 
al., 2008) 
p19ARF CAGGAGCATGGGTCGCA
GGT 
GGTCGGGAGAGGGTGGTGGG (Bastide et 
al., 2008)  
E2F-5 GGACCAATCCATGTGC AGGAGACAGCCGTAAG - 
VEGF GCGAGGCAGTTGAGT GGCGAATCCAGTTCCACG - 
NR4a3 AGCATTGGGTGACTCGA
T 
AACACGGAATGTTGAACCGTA - 
TFAM AGACCTCGGTCAGCATA
TAACA 
GCGACGGATGAGATCACTT  
NRF-1 GCTTGCGTCGTCTGGAT GCACCGTGTCGCTCAT  
PGC-1α GGTCCCCAGGCAGTAG CTCCATCATCCCGCAG  
MCP-1 GCAGGTCTCTGTCACGCT
TCT 
GGCTGAGACAGCACGTGGAT  
SERCA-2 TTCCGTTACCTGGCTATT CATCGGATACGGGGAC  
NCX ATGCTTCGACTAAGTCTC
CCA 
ACAAAATACACAGTTGCTCTAG  
Osteopontin CCAGCACACAAGCAGAC
GTT 
TCAGTCCATAAGCCAAGCTATCAC (Heyen et 
al., 2002) 
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4.15 Biochemical analyses 
Blood glucose was determined with a handheld test meter (Contour, Bayer Diabetes Care, Basel, 
Switzerland), and plasma BNP (BNP-45, Peninsula Laboratories, Belmont, CA, USA), plasma renin 
activity (Angiotensin I RIA kit, Diasorin, Italy), serum aldosterone (Coat-a-Count Aldosterone RIA 
kit, DPC Biermann, Bad Nauheim, Germany) and serum insulin (Rat insulin RIA kit, Linco, St. 
Charles, Missouri, USA) were determined by radioimmunoassay according to the manufacturers’ 
instructions. Urinary noradrenalin and dopamine were analysed using the isocratic ion-pair reversed-
phase high-performance liquid chromatography method with electrochemical detection. (Helkamaa et 
al., 2003) Urinary albumin was measured by ELISA using rat albumin as a standard (Celltrend, 
Luckenwalde, Germany). Plasma samples were analysed for levosimendan and OR-1896 by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) (Kivikko et al., 2003). 
 
4.16 Statistical analyses 
Data are presented as means ± standard error of mean. Statistically significant differences in mean 
values were tested by analysis of variance (ANOVA) and Tukey’s and Bonferroni’s post-hoc test for 
comparisons of multiple groups. The Kaplan-Meier test was used for survival analysis. 
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5 Results 
5.1 Survival (All studies) 
When kept on high-salt diet, Dahl/Rapp SS rats develop fulminant hypertension and severe end-organ 
damage, with a mortality of almost 100% after 8 weeks. During 7-week follow-up period Dahl/Rapp 
SS rats on a high-salt diet exhibited total mortality of 62%, significantly more than mortality rate of 
0% in similar rats on a low-salt diet. Both levosimendan and OR-1896 were able to significantly 
improve survival. Of levosimendan treated groups, higher dose yielded a survival rate of 75% and a 
lower dose 100%. Both OR-1896 doses were able to improve survival in a similar manner; 75% of the 
Dahl/Rapp SS rats on a high-salt diet survived (Figure 6). Interestingly, also late treatment, started at 
midpoint of the 7-week follow-up prevented mortality in both levosimendan, and OR-1896-treated 
rats (survival rates of 80% and 58% vs 38% in untreated Dahl/Rapp rats on high-salt diet). 
 
Figure 6. Survival curves of Dahl/Rapp SS rats on high salt diet treated with levosimendan (0.3 (low) and 3 
(high) mg/kg) and OR-1896 (0.02 (low) and 0.2 (high) mg/kg) compared to untreated Dahl/Rapp SS rats on 
high salt diet and on low salt diets. * denotes p<0.05 compared to Dahl/Rapp SS rats on high salt diet. 
 
Survival after MI is impaired in the presence of diabetes. In diabetic GK rats, survival rate after LAD-
induced MI was only 35%, while the survival rate of non-diabetic Wistar rats was 58% (p<0.05). 
Neither levosimendan nor OR-1896 had effect on mortality. 
 
5.2 Cardiac functions and blood pressure (All studies) 
A high-salt diet induced moderate deterioration of cardiac functions and left ventricular hypertrophy 
in Dahl/Rapp SS rats when assessed by echocardiography. The ejection fraction and fractional 
shortening decreased slightly in Dahl/Rapp SS rats on a high-salt diet. Both levosimendan doses and 
the higher dose of OR-1896 significantly improved contractility and normalized ejection fraction and 
fractional shortening, even over the levels found in Dahl/Rapp SS rats on a low-salt diet. 
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Echocardiography revealed post-infarct heart failure in GK and Wistar rats with an ejection fraction 
20-40% (p<0.05) at different time points. In GK rats, levosimendan increased ejection fraction, 
fractional shortening and cardiac output to levels found in sham-operated GK rats. However, 
administered levosimendan in non-diabetic Wistar rats was clearly less beneficial. In sham-operated 
GK or Wistar rats, levosimendan did not significantly influence cardiac function. In post-infarct GK 
rats, OR-1896 also increased ejection fraction and fractional shortening at all time-points but 
significant increase in cardiac output was only seen in the later stages of remodelling. 
A high-salt diet induced fulminant hypertension in Dahl/Rapp SS rats (215 mmHg vs. 148 mmHg, 
p<0.05). Both levosimendan doses and the higher dose of OR-1896 produced a slight decrease in 
blood pressure in the middle of 7-week follow-up period but at the end of experiment all groups had 
similar blood pressure values. 
In diabetic GK rats, MI resulted in approximately 30 mmHg lower blood pressure (p<0.05) than in 
SHAM operated rats. Levosimendan or OR-1896 had no effect on blood pressure in Wistar rats or MI 
operated GK rats, but in SHAM operated GK rats both levosimendan and OR-1896 treatments 
resulted in an approximately 30 mmHg reduction in blood pressure compared to non-medicated 
SHAM-operated rats. 
 
5.3 Hypertrophy (All studies), cardiomyocyte cross-sectional area (Study III and IV) 
Dahl/Rapp SS rats on a high-salt diet showed a markedly elevated heart weight to body weight ratio 
compared with low-salt controls (5.0 ± 0.15 mg/g vs. 3.0 ± 0.07 mg/g, p<0.001). Treatment with 
levosimendan or OR-1896 was able to partially prevent cardiac hypertrophy measured by the heart 
weight/body weight ratio in hypertensive Dahl/Rapp SS rat. MI induced pronounced cardiac 
hypertrophy measured as heart-weight-to-body weight ratio 1, 4 and 12 weeks post-MI (increase of 
61%, 62% and 71%, respectively, p<0.01, when compared with age-matched SHAM and MI-operated 
GK rats). 
MI induced 55% increase in cardiomyocyte cross-sectional area in the diabetic GK rat (Figure 7), 
which was preventable with both treatments. Levosimendan and OR-1896 also lowered diabetes-
induced elevation of cardiomyocyte cross-sectional area in SHAM-operated GK rats by 7%. In Wistar 
rats MI induced an increase in cardiomyocyte cross-sectional area relative to SHAM-operated rats 
(372.3 ± 7.8 µm2 vs. 271.6 ± 5.4µm2, p<0.001). Levosimendan further elevated cardiomyocyte cross-
sectional area by roughly 45 µm2. 
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Figure 7 MI induced a clear hypertrophic response, measured as cardiomyocyte cross-sectional area, 12 weeks 
post-MI in GK and Wistar rats. Oral levosimendan and OR-1896 treatments were able to prevent hypertrophic 
activation and to reduce cross-sectional area even in SHAM-operated GK rats. Levosimendan had no effect on 
cross-sectional area in Wistar rats. * p<0.05 compared with GK or WIS MI, # p<0.05 compared with GK or 
WIS SHAM 
 
5.3.1 Cardiomyocyte morphology (Studies I and II), infarct size, fibrosis (Studies III and IV) 
Dahl/Rapp SS rats on a high-salt diet developed clear coronary damage and to lesser extent 
myocardial damage. Animals showed intimal hyperplasia, fibrinoid necrosis of the arteries with 
marked medial thickening and adventitial scarring, myocardial infarcts with inflammation, 
perivascular monocyte/macrophage infiltration and p47phox (subunit of ROS-generating NAPDH 
oxidase) expression by immunohistochemistry. Neither levosimendan nor OR-1896 treatment had an 
effect on the coronary or myocardial damage score. 
LAD ligation resulted in an infarction size of approximately 37% in diabetic GK rats and 32% in 
Wistar rats. Levosimendan or OR-1896 treatments had no effect on infarct size.  
Interstitial collagen volume fraction tended to be increased after MI in GK and Wistar rats, but this 
change did not quite reach statistical significance. Levosimendan treatment tended to decrease remote 
area collagen volume fraction in MI-operated rats, while interstitial collagen volume fraction in sham-
operated GK rats was unaffected (p=0.34). 
In both GK and Wistar rats, MI also induced mRNA expression of CTGF, a potent inductor of 
fibrosis, throughout the 12-week follow-up with the most prominent induction one week after 
infarction. Both treatment with levosimendan and treatment with OR-1896 were able to prevent this 
fibrotic signalling. 
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5.4 Calcium handling proteins (Studies I and III) 
Development of heart failure is associated with disturbances in calcium handling. In hypertension and 
diabetic MI, myocardial SERCA2 expression was decreased by 40% and 30%, respectively. 
Hypertension in Dahl/Rapp SS rats had no effect on myocardial NXC expression, but MI induced a 
74% increase in NCX protein expression in GK rats. MI had no impact on expression of calcium 
handling proteins in Wistar rats. Levosimendan was able to prevent abnormalities in expression of 
calcium handling proteins in both Dahl/Rapp SS rats and GK rats. 
 
5.5 Expression of natriuretic peptides (All studies) 
Hypertension induced a 5-fold expression of atrial natriuretic peptide (ANP) in Dahl/Rapp SS rats and 
a 50% non-significant induction of brain natriuretic peptide (BNP) accompanied by increased BNP 
plasma levels. A higher dose of levosimendan was able to reduce myocardial ANP-mRNA expression 
to a level similar to that found in Dahl/Rapp SS low-salt controls, and both doses were able to 
normalize BNP in both mRNA level and plasma. 
In GK rats, MI induced a significant increase in ANP mRNA (Figure 8) as well as a slight, non-
significant increase in plasma BNP throughout the 12-week follow-up. Post-infarct Wistar rats also 
showed increased expression of ANP mRNA. Levosimendan and OR-1896 were able to normalize 
expressions of myocardial natriuretic peptides. 
 
Figure 8 Expression of ANP mRNA during post-infarct remodelling in GK and Wistar rats 1, 4 and 12 weeks 
after MI. Levosimendan and OR-1896 normalized ANP mRNA expression in GK rats, while levosimendan had 
no effect on ANP mRNA expression in Wistar rats. * p<0.05 compared with GK MI, # p<0.05 compared with 
GK SHAM. 
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5.6 Apoptosis (Studies I and III) 
Cardiomyocyte apoptosis was assessed by TUNEL staining (Figure 9) and apoptosis-specific 
microarray. In hypertensive Dahl/Rapp SS rats on a high-salt diet cardiomyocyte apoptosis was 
increased by 6-fold compared with low-salt controls. Levosimendan dose-dependently decreased the 
number of apoptotic cardiomyocytes in Dahl/Rapp SS rats on a high-salt diet.  
Both GK and Wistar rats exhibited increased cardiomyocyte apoptosis after MI, but the degree of 
apoptosis was higher in GK rats. Cardiomyocyte apoptosis was more prominent in the border than in 
the remote area (Figure 8). Based on microarray experiments, a >1.8 fold increase in mRNA 
expression was found in 90% (103/114) of selected apoptotic genes in GK rat hearts after MI. Wistar 
rats also showed induction of apoptosis, but based on microarray analysis the profile of apoptotic 
expression was different from that in GK rats. Levosimendan significantly reduced sustained 
cardiomyocyte apoptosis in both border and remote areas and prevented induction of apoptotic genes 
in the heart after MI. Levosimendan suppressed mRNA expression of apoptosis-related genes on a 
broad range, several member of apoptosis-related caspases (including caspase 9), tumour necrosis 
superfamily and BCL-pathway. 
MI induced a 2-fold increase in proapoptotic DNA-bound, nuclear FOXO3a, followed by a 100% 
increase in FOXO3a controlled atrogin-1 mRNA expression in the GK heart. Levosimendan 
prevented MI-induced activation of transcription factor FOXO3a and atrogin-1. Furthermore, 
apoptotic microarray results revealed that FOXO3a -associated proapoptotic genes, such as Bcl2l11, 
Bad and Fadd, were induced in GK rats with MI compared with SHAM controls. Levosimendan was 
able to suppress apoptotic signalling caused by myocardial infarction.  
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Figure 9. Effects of oral levosimendan treatment on cardiomyocyte apoptosis in border (A) and remote (C) 
areas in infarcted GK hearts and in hearts of Dahl/Rapp SS rats on high salt diet (B). * p<0.05 compared with 
GK SHAM or DAHL HS, # p<0.05 compared with GK MI or DAHL LS. 
 
5.7 Premature cardiomyocyte senescence (Studies II and IV) 
A high-salt diet induced a 4-fold change in p16INK4a mRNA expression in Dahl/Rapp SS rats, while 
expression of tumour suppressor p19ARF mRNA remained unaltered (Figure 10). OR-1896 treatment 
was able to reduce p16INK4a mRNA expression and induce p19ARF mRNA expression. The p16INK4A-
positive staining in cardiac samples was located in the nuclei of myocytes, arterial smooth muscle 
cells and to a lesser extent in vascular endothelial cells. The perivascularly located leucocytes also 
showed positive staining. 
MI induced a clear, 5-fold induction in the cardiomyocyte senescence marker p16INK4a at later stages 
of post-infarct remodelling in GK rats, while induction of p19ARF was most prominent at the early 
stages of remodelling (Figure 10). MI had no effect on p16INK4a mRNA expression in Wistar rats. 
Transcription factor, cell cycle suppressor E2F-5 mRNA was induced parallel to p16INK4a expression 
in post-infarct GK rats. Oral OR-1896 treatment was able to completely normalize myocardial p19ARF 
mRNA expression and to prevent upregulation of myocardial p16INK4A and E2F-5 mRNA expressions. 
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Figure 10. Induction of senescence markers p16INK4A and p19ARF mRNA during hypertensive remodelling in 
Dahl/Rapp SS rats (A and B) and after myocardial infarction in spontaneously diabetic GK rat (C and D). Oral 
OR-1896 was able to prevent upregulation of p16INK4A mRNA in both rat strains and induce potentially 
protective p19ARF mRNA in Dahl/Rapp SS rats. * p<0.05 compared with Dahl HS or GK MI, # p<0.05 
compared with Dahl LS. 
 
5.8 VEGF, NR4a3 and MCP-1 expression (Study IV) 
VEGF, NR4a3 and MCP-1 mRNA expression were measured as markers of inflammation and 
oxidative stress. VEGF mRNA expression was transiently reduced 1 week after MI in GK rats, with 
induction of expression occurring later in remodelling (unpublished data). A VEGF-induced increase 
in nuclear factor NR4a3 mRNA expression was seen at 12 weeks post-MI, while a smaller increase 
was also seen earlier in post-MI remodelling. MCP-1 mRNA expression was measured as a marker of 
VEGF- and NR4a3-induced oxidative stress. (Martinez-Gonzalez and Badimon, 2005, Liu et al., 
2003, Pols et al., 2007) MCP-1 mRNA expression was upregulated during post-MI cardiac 
remodelling in a similar manner as VEGF mRNA expression, resulting in a >3.5-fold induction 12 
weeks after MI. OR-1896 was able to prevent the late induction of VEGF, even to lower levels than 
observed in SHAM-operated animals and to reduce NR4a3 mRNA expression throughout the study. 
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OR-1896 treatment completely prevented induction MCP-1 mRNA, indicating reduced oxidative 
stress. 
 
5.9 Expression of markers of mitochondrial biogenesis (Study IV) 
To study the mitochondrial biogenesis, mRNA expression of typical markers of mitochondrial 
biogenesis, NRF-1, TFAM and PGC-1α, were measured. MI induced a significant increase in 
myocardial mRNA expression of NRF-1, while expressions of PGC-1α and TFAM showed only a 
positive trend towards increased expression. Oral OR-1896 was able to reduce NRF-1 expression to 
levels found in SHAM-operated rats, with similar trend in PGC-1 and TFAM mRNA expressions. 
 
5.10 Biochemical and hormonal analyses (All studies) 
A high-salt diet induced clear renal damage, measured by urinary albumin (113.3 ±44.2 vs 52.4 
±36.4, p<0.05) but no differences in plasma renin activity, serum aldosterone or urinary noradrenalin 
in Dahl/Rapp SS rats when compared to low salt controls. Levosimendan had no effect on urinary 
albumin, plasma renin activity or serum aldosterone, but OR-1896 was able to reduce serum 
aldosterone by 50% (p<0.05) compared with both high- and low-salt controls. 
In GK and Wistar rats, neither MI nor levosimendan treatment influenced plasma renin activity, 
plasma glucose, serum insulin, serum aldosterone or urinary albumin.  
 
5.11 Plasma drug concentrations (All studies) 
The mean levosimendan daily dosages of low- and high-dose levosimendan in Dahl/Rapp SS rats 
were 0.36 ± 0.01 and 3.6±0.1 mg/kg, respectively. The mean plasma concentrations of levosimendan 
and OR-1896 in the low-dose levosimendan group were 6.4 ± 1.3 and 4.5 ± 0.2 ng/ml and in the high 
dose levosimendan group 79 ± 19 and 42 ± 15 ng/ml. Plasma levosimendan concentration showed 
typical diurnal variation with the highest plasma concentrations occurring during the night (Figure 
11). 
The respective average daily dosages for OR-1896 in Dahl/Rapp SS rats were 192 ± 24 µg/kg for the 
high-dose OR-1896 group, and 19 ± 4 µg/kg for the low-dose OR-1896 group, resulting in steady 
diurnal blood drug concentrations (Figure 11). The mean 24-h plasma concentrations of OR-1896 in 
the high- and low–dose groups were 49.1 ± 10.6 and 4.1 ± 0.43 ng/ml, respectively. 
At the end of the study in GK rats treated with levosimendan, the plasma concentrations of OR-1896 
were 20.4 ± 10.5 ng/ml. In GK rats treated with OR-1896, the mean plasma concentration of OR-1896 
was 20.1 ± 2.0 ng/ml.  
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Figure 11. Mean plasma concentrations of levosimendan (A) and OR-1896 (B) after oral levosimendan or OR-
1896 treatments (C) in hypertensive Dahl/Rapp SS rat on a high-salt diet. 
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6 Discussion 
 
Despite of marked advancements in understanding the molecular mechanisms behind development of 
heart failure and in the treatment options available, a great deal remains to be elucidated. Current 
standard treatment with drugs affecting to the renin-angiotensin-aldosterone and sympatoadrenergic 
systems have strong preventive effect on mortality, but is not able to improve already lost cardiac 
capacity. Moreover the ageing population and unfavourable lifestyle choices, including tobacco, 
alcohol, unhealthy nutritional composition and lack of physical activity increase the prevalence of the 
heart failure and add strain to the public health care systems. Thus, demand for new, effective ways to 
prevent harmful cardiac remodelling and improve cardiac pumping capacity are being sought. (Kupari 
and Lommi, 2004) 
Our study demonstrated that chronic oral treatment with the calcium sensitizers levosimendan and its 
active metabolite OR-1896 provides a safe and efficient means of preventing mortality and end-organ 
damage in hypertensive heart disease, and improve cardiac functions and preventing deleterious 
cardiac remodelling in a post-infarct model complicated with type II diabetes. 
 
6.1 Methodological aspects 
6.1.1 Validation of the models 
Hypertension and associated left ventricular hypertrophy are powerful risk factors for severe cardiac 
conditions. Left ventricular hypertrophy reduces diastolic relaxation, renders heart susceptible to 
ischaemia and increases the risk of cardiac arrhythmias and sudden death. (for review see (Artham et 
al., 2009)) To study the heart failure with preserved systolic function, the type of heart failure often 
related to hypertension and left ventricular hypertrophy in humans, hypertensive Dahl/Rapp SS rat 
was used. 
The Dahl/Rapp SS rat is a model of salt-sensitive hypertension. It represents the early phase in the 
progression of hypertensive heart failure, with increased left ventricular hypertrophy and impaired 
diastolic functions. When fed a diet containing 6% NaCl, the rats develop severe hypertension and 
end-organ damage with markedly increased cardiac hypertrophy, myocardial infarctions and severely 
impaired renal function. Mortality approaches 100% after 7 weeks on the high-salt diet. Surprisingly 
though, cardiac functions of Dahl/Rapp SS hearts remain at relative high level (Klotz et al., 2006). In 
our studies, the average decrease in ejection fraction was roughly 5%, which is not enough to explain 
the increased mortality. However, hypertensive Dahl/Rapp SS exhibit clear cardiac hypertrophy with 
increased left ventricular wall thickness, indicating the presence of heart failure with preserved 
systolic function. Increased left ventricular hypertrophy is associated with hypoxia and cardiac 
arrhythmia, and regression of the left ventricular hypertrophy by angiotensin II blockade prevents 
ischaemia-induced lethal arrhythmias. (Kohya et al., 1995) Indeed, the actual cause of death in 
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Dahl/Rapp SS rats seems to be sudden death, due to hypertrophy related cardiac arrhythmias, and 
strokes rather than heart failure (Qu et al., 2000). 
Diabetes is a known risk factor for cardiovascular diseases, and diabetes increases the risk of first 
time myocardial infarction by 5-fold (Bauters et al., 2003). As 15-20% of heart failure patients are 
diabetics, we wanted to investigate the post-infarct remodelling in a situation complicated with 
diabetes. Heart failure was produced by ligation of the left ascending coronary artery (LAD), widely 
used experimental heart failure model, in diabetic GK rats. Wistar rats were used as non-diabetic 
controls. GK rats have heterogenic, spontaneous type II diabetes, which is not associated with obesity, 
providing a good model for type II diabetes found in humans. We noted that survival of myocardial 
infarction was impaired in diabetic GK rats compared with non-diabetic Wistar rats, leading to a 
higher number of animals needed for the studies. To improve survival of GK rats, 1 IU of long-acting 
insulin was used to reduce the ketamin-induced increase in blood glucose values, but the difference in 
survival remained significantly different. The level of cardiomyocyte hypertrophy, inflammation 
status and apoptosis were also affected by diabetes, with GK rats exhibiting larger cardiomyocytes, 
greater activation of inflammation and more cardiomyocyte apoptosis than non-diabetic Wistar rats. 
 
6.2 Cardiovascular effects of oral levosimendan and OR-1896 
6.2.1 Mortality 
Clinical data on levosimendan’s effects on mortality remain conflicting. Earlier reports showed 
beneficial, long-lasting effect on improved survival (Follath et al., 2002, Moiseyev et al., 2002, Zairis 
et al., 2004), which were not confirmed by later, larger studies on both iv and oral levosimendan 
(Packer, 2005, Nieminen et al., 2008). 
In present study hypertensive Dahl/Rapp SS rats exhibited increased mortality when compared to 
normotensive ones. Especially interesting is that both oral levosimendan and OR-1896, also started 
after development of hypertension, were able to significantly reduce or totally prevent mortality 
without changes in systolic blood pressure or renal functions. Due to the relatively preserved systolic 
function in hypertensive Dahl/Rapp SS rats it seems reasonable to assume despite that minor 
significant improvement in cardiac functions by levosimendan or OR-1896 other mechanisms than 
pure inotrophy are also associated. Interestingly, levosimendan has been shown to prevent ventricular 
tachyarrhythmias in ischaemia-reperfusion models (Papp et al., 2006, Du Toit et al., 1999), which 
could at least partly explain improved survival in levosimendan medicated Dahl/Rapp SS rats, found 
in a present study. Levosimendan and OR-1896 could also have mediated improved survival via 
reduction in left ventricular hypertrophy as regression of left ventricular hypertrophy has also been 
shown to improve diastolic functions and decrease cardiac arrhythmias and sudden cardiac death in 
hypertensive patients, even without reduction of blood pressure (Okin et al., 2006, Wachtell et al., 
2002). 
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Diabetes is linked to increased mortality after MI (Laakso, 2001). In good accordance with previous 
knowledge, acute mortality from MI was higher in diabetic GK rats compared to non-diabetic controls 
despite of peri-operative glucose control and similar size of experimental infarctions (Goyal et al., 
2009). The underlying molecular mechanisms behind increased mortality are not clearly defined, but 
it is evident that present diabetic cardiomyopathy with compensatory cardiac hypertrophy, increased 
apoptotic signalling and vulnerability to ischaemia-induced arrhythmias play a major role in it 
(Marwick, 2008). 
In GK rats with MI most of the mortality took place during first 24 h after MI, before the study 
treatments were started. It has been shown that cardiomyocyte damage and necrosis is evident 6-hours 
after MI (Vivaldi et al., 1985), well before treatments were started in a present study. This 24 h delay 
before beginning of the treatments was done to select those individuals with none-fatal MI in order to 
study the effects of levosimendan or OR-1896 on existing, chronic heart failure. However, this 
approach limits the correlation to clinical situation where treatment would be started as sooner. 
During follow up, there were only few occasional deaths in GK rats and due to relatively small 
sample size and short follow up neither levosimendan nor OR-1896 had effect on long-term mortality 
in a present study. 
 
6.2.2 Cardiac functions and remodelling 
Transition from the left ventricular hypertrophy to the heart failure is associated with complicated 
network of molecular mechanisms, which remodel cardiac structure and functions (Wright et al., 
2008). In this study both hypertension and myocardial infarction resulted in signs of cardiac 
remodeling, namely clear cardiac hypertrophy, measured by heart weight to body weight ratio or 
cardiomyocyte cross sectional area, and increased fibrotic cardiac remodeling with compromised 
cardiac contractility. 
In this study hypertensive Dahl/Rapp SS rats had severe hypertension, clear cardiac hypertrophy and, 
as described previously, only modest impairment in systolic functions (Klotz et al., 2006). Oral 
levosimendan and OR-1896 were both able to improve cardiac function even above levels found in 
low salt controls and reduce cardiac hypertrophy. As reduction of left ventricular hypertrophy by 
antihypertensive agents has been shown to be beneficial in hypertensive patients (Gupta et al., 2007, 
Lorell and Carabello, 2000), temporary reduction in blood pressure could have been partially 
responsible with reduced left ventricular mass and improved contractility discovered in a present 
study in treatment groups. However, it should be noted that levosimendan or OR-1896 had no effect 
terminal blood pressure indicating improvement in cardiac hypertrophy by another mechanisms, such 
as improved microcirculation or reduced inflammation or apoptosis, which are discussed further. 
Levosimendan and OR-1896 were able to reduce plasma BNP concentration and myocardial mRNA 
expression of ANP in hypertensive Dahl/Rapp SS rats, indicating a decrease in myocardial tension 
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and cardiac overload (Haug et al., 1993). This could have been lead to improved cardiac 
microcirculation, improved oxygen delivery and improved cardiac performance. 
Besides cardiac functions, it should also be noted, that Dahl/Rapp SS rats on a high-salt diet exhibited 
marker albuminuria and renal damage. Levosimendan or OR-1896 was unable to alleviate renal 
damage caused by severe hypertension indicating that beneficial effects discovered in a present study 
were not mediated either by renal protection. Interestingly though, in humans levosimendan has been 
shown to improve renal function (Yilmaz et al., 2007, Zemljic et al., 2007). 
Development of post-infarct heart failure was assessed 1, 4 and 12 weeks after MI in diabetic GK rats. 
MI resulted severe pumping failure, which, like in humans (Sezer et al., 2009), was moderately 
compensated over time. Oral levosimendan and OR-1896 were able to totally normalize cardiac 
function without any effects on infarct size, cardiac morphology, blood pressure or diabetic status. 
Since cardiac output is directly related to heart rate and stroke volume (Heikkilä et al., 2008), 
levosimendan and OR-1896-induced normalization of cardiac output in GK rats, could have been 
partially due to drug-induced increase in heart rate. It is possible that the increased in heart rate found 
in the present study in levosimendan-treated GK rats are rather due to PDE III inhibition (Kaheinen et 
al., 2006, Ajiro et al., 2002, Szilagyi et al., 2005). However, it should be noted that in Wistar rats with 
MI levosimendan was able to improve cardiac output without elevation in heart rate. 
Oxidative stress plays a major role in post-infarct cardiac remodelling and suppression of ROS 
protects the heart (Sun, 2007). In GK rats MI induced clear hypertrophic response, measured by 
increased cardiomyocyte cross sectional area, profibrotic CTGF mRNA expression and interstitial 
fibrosis, associated with increased diabetic oxidative stress (Vahtola et al., 2008). Interestingly, in GK 
rats oral levosimendan or OR-1896 were able to suppress oxidative stress and inflammation, 
measured by several different markers, which could explain the observed reduction in the cardiac 
hypertrophy and alleviation of the fibrosis. 
Interestingly, effects of levosimendan were more beneficial in diabetic GK rats than in 
normoglycemic Wistar rats. Mechanisms behind this are not clearly defined yet, but it could be 
argued that alleviating effects of levosimendan and OR-1896, on diabetes induced inflammation, 
fibrotic response, imbalance in expression of calcium handling proteins and apoptosis are involved 
(Adamopoulos et al., 2006b, Parissis et al., 2004b, Trikas et al., 2006). However, further clinical 
studies on diabetic subjects are warranted to clarify whether levosimendan greater efficacy it seen also 
in humans. 
 
6.2.3 Calcium handling 
Altered calcium handling has been shown to play a major role in development of heart failure (Bers, 
2002, Hasenfuss and Pieske, 2002). Both experimental studies and failing human hearts show reduced 
SERCA2 protein level and activity, which leads to reduced uptake of calcium to SR, impairment of 
relaxation and longer duration of calcium transients (Zarain-Herzberg et al., 1996, Seki et al., 2003a, 
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Schmidt et al., 1998, Okayama et al., 1997, Meyer et al., 1995, Aoyagi et al., 1999). Interestingly, 
altered insulin signalling has also been linked to reduced myocardial expression of SERCA2 after MI 
(Sena et al., 2009). Consistent with the previous results (Seki et al., 2003a, Yoneda et al., 2001, Sena 
et al., 2009), both hypertensive Dahl/Rapp SS rats and diabetic GK rats revealed hindered expression 
of myocardial calcium handling proteins, namely SERCA2 and NCX, leading to impaired calcium 
handling, while non-diabetic Wistar rats showed no post-MI changes in calcium handling protein 
expressions. Oral treatment with levosimendan normalized the SERCA2 to NCX ratio in Dahl/Rapp 
SS and diabetic GK rats. In fact, levosimendan-corrected impaired calcium handling in GK rats could 
explain the beneficial effects of levosimendan treatment in the presence of diabetes as increased 
expression SERCA2 in diabetic SERCA2-transgenic mice has been previously shown to improve 
cardiac contractility (Vetter et al., 2002). 
Reactive oxygen species (ROS) have been noted to have a detrimental effect on calcium handling 
proteins, such as SERCA2 and NCX (Guerra et al., 1996, Goldhaber, 1996, Kaplan et al., 2003). In 
addition to disturbances in calcium handling protein expression, hypertensive Dahl/Rapp SS and 
diabetic GK rats showed activation of several markers of inflammation, namely p47phox, MCP-1, IL-
6 and osteopontin. In addition to its effects on calcium handling proteins, levosimendan was able to 
reduce inflammatory status in both heart failure models used. Terentyev et al. recently showed, that 
antioxidant treatment is improves function of another calcium handling protein, ryanodine receptor, 
indicating that reduced inflammatory status might explain improved calcium handling found in this 
study (Terentyev et al., 2008). 
 
6.2.4 Apoptosis 
Increased apoptosis has been linked to development and progression of heart failure in both clinical 
and experimental setting (Narula et al., 1996, Olivetti et al., 1997a, Kang and Izumo, 2000). In good 
agreement with previous knowledge, the present study showed elevated levels of cardiomyocyte 
apoptosis associated with hypertension and post-infarct cardiac remodelling (Narula et al., 1996, 
Olivetti et al., 1997a, Kang and Izumo, 2000). The level of post-infarct apoptosis was more elevated 
in the presence of diabetes, and diabetic animals had different profiles in apoptotic microarray 
analyses examining expression of genes involved in apoptotic events than their normoglycaemic 
controls. In diabetic GK rats, oral levosimendan reduced the number of apoptotic cardiomyocytes to a 
level similar to that found in SHAM-operated GK rats. 
The exact mechanisms related to reduced cardiomyocyte apoptosis remain under investigation, but 
ROS and ATP-sensitive potassium channels apparently play a major role in apoptosis (for reviews see 
(Giordano, 2005, Ardehali and O'Rourke, 2005)). Levosimendan is a known opener of sarcolemmal 
and mitochondrial ATP-sensitive potassium channels (Kopustinskiene et al., 2004, Kopustinskiene et 
al., 2001), and it has previously been shown to reduce plasma markers of apoptosis in human plasma 
and cell cultures (Adamopoulos et al., 2006b, Parissis et al., 2004b, Maytin and Colucci, 2005). The 
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present study revealed for the first time the effectiveness of chronic levosimendan treatment in 
preventing heart failure-related cardiomyocyte apoptosis in two different experimental models. 
Microarray analysis also showed that levosimendan is able to suppress all apoptotic signalling at the 
mRNA level. Levosimendan also reduced activity of proapoptotic transcription factor FOXO3A and 
downregulated its downstream signalling. Based on this finding, PDE III inhibiting properties of 
levosimendan appear not to be clinically relevant, as traditional pharmacological PDE III inhibitors 
have been linked to increased apoptosis in patients with heart failure (Ding et al., 2005). Whether 
levosimendan is also able to suppress apoptosis in an actual clinical setting remains a subject for 
further clinical studies. 
ROS play a major role in several physiological processes, such as control of apoptosis. However, an 
elevated level of oxidative stress, as often found in heart failure, can lead to several types of tissue 
damage, including activated apoptosis (for review see (Giordano, 2005)). In the present study, 
levosimendan reduced markers of systemic inflammation in both animal models used, indicating that 
besides KATP opening properties antiapoptotic effects of levosimendan could be, at least partially, 
mediated via reduction of oxidative stress. Indeed, improved oxidative status prevents apoptosis in 
different experimental approaches (Dekkers et al., 2008, Zhao et al., 2009, Looi et al., 2008). 
Especially reduction of VEGF-controlled NR4a3 mRNA expression indicates the beneficial role in 
suppression of ROS-induced apoptosis, as OR-1896 was able to significantly reduce MI-induced 
mRNA expressions of VEGF, NR4a3 and MCP-1 mRNA expressions (Martinez-Gonzalez and 
Badimon, 2005, Liu et al., 2003, Pols et al., 2007). 
 
6.2.5 Cardiomyocyte senescence 
Activation of premature senescence has recently been linked to several pathological conditions such 
as premature ageing, hypertension and heart failure (Westhoff et al., 2008, Sharpless and DePinho, 
2007, Melzer, 2008). Human hearts with premature cardiac ageing and heart failure show an 
accumulation of p16INK4a positive primitive cells and myocytes combined with shortened telomeres, 
representing the imbalance between cellular growth and death (Chimenti et al., 2003). The INK4a/ARF 
locus codes the cell cycle inhibitor p16INK4A and the p53 activator p19ARF, which have been related to 
premature senescence (For review see (Sharpless, 2004, Sharpless and DePinho, 2007, Melzer, 2008). 
In our study, hypertensive Dahl/Rapp SS rats presented along with fulminant hypertension and severe 
tissue damage also activation of cardiomyocyte senescence, measured as 4-fold increase in p16INK4a 
mRNA. These results are in accordance with previous findings by Westhoff et al, who showed 
hypertension-induced cardiac senescence, mechanistically linked to increased renin-angiotensin 
activity. (Westhoff et al., 2008) Ang II has been demonstrated to induce cellular senescence via 
NADPH oxidase-derived oxidative stress and DNA damage. (Herbert et al., 2008) As increased ROS 
formation plays a major role in development of target-organ damage in Dahl/Rapp SS rats (Tojo et 
al., 2002), it seems reasonable to assume that discovered activation of cardiomyocyte senescence is 
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truly mediated via increased oxidative stress. Treatment with chronic OR-1896 administration was 
able to completely prevent induction in expression of p16INK4A mRNA independent of blood pressure 
status or renin-angiotensin system activity. However, both levosimendan and OR-1896 have been 
shown by us and others to reduce markers of inflammation, which provide a possible mechanistic 
explanation for discovered prevention of senescence (Parissis et al., 2007, Louhelainen et al., 2007, 
Adamopoulos et al., 2006a, Parissis et al., 2004a). 
Myocardial infarction induced a clear senescent response in diabetic GK rats. Myocardial mRNA 
expression of p19ARF was induced immediately after MI, with the most prominent expression 
occurring during the early weeks of remodelling. However, p16INK4a mRNA was expressed several-
fold only at later stages of remodelling. Thus, the present findings support the results of Baker et al, 
who reported that p19ARF functions as a protective factor to alleviate MI-induced trauma. (Baker et 
al., 2008a) By contrast, induction of p16INK4A in late remodelling seems to be linked more to ageing 
and diabetes-induced tissue damage than plain MI. (Rota et al., 2006) Further induction of senescent 
cascades was examined by mRNA expression of transcription factor E2F-5, which has been shown to 
be a key downstream mediator for p16INK4a-induced G1 arrest (Ohtani et al., 2003, Gaubatz et al., 
2000). E2F-5 mRNA expression was induced along with p16INK4A mRNA expression, indicating a 
true senescent activation.  
In GK rats, post-infarct chronic treatment with OR-1896 was able to completely prevent upregulation 
of senescent signalling, measured by p19ARF, p16INK4a and E2F-5 mRNA expressions. Mechanisms for 
this prevention of senescence remain unclear, but involvement of reduced oxidative stress via 
treatment is likely to play a major role. 
Taken together, this novel senescence preventing effect of calcium sensitizers levosimendan and OR-
1896 provides intriguing possibilities for future treatment and prevention of heart failure. However, 
studies with human subjects are warranted to clarify the effectiveness in clinical use. 
 
6.2.6 Mitochondrial biogenesis 
Failure in normal mitochondrial functions has been shown to play a major role in energetics of failing 
heart (Rimbaud et al., 2009), with special emphasis with type 2 diabetes (Sack, 2009). In the present 
study, markers of mitochondrial biogenesis, namely TFAM, PGC-1α and NRF-1, were evaluated in 
the hearts of spontaneously diabetic GK rat after MI. NRF-1 mRNA expression was induced after MI 
as compared to SHAM-operated animals. NRF-1 regulates a majority of the genes involved in 
mitochondrial respiratory function (for review see (Scarpulla, 2008)). NRF-1 offers a link between 
mitochondrial biogenesis and oxidative stress, as it is induced via NRF-2 –dependent manner in 
response to CO-induced oxidative stress (Piantadosi et al., 2008). Sano and Fukuda recently 
speculated that mitochondrial biogenesis can in fact be triggered by low-dose formation of ROS (Sano 
and Fukuda, 2008). In the present study mRNA expression of NRF-1 was significantly induced with 
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similar trend towards increased mRNA expressions on TFAM and PGC-1α. Interestingly, OR-1896 
treatment prevented the MI-induced increase in mitochondrial biogenesis markers, thus supporting 
further OR-1896’s anti-inflammatory effects. 
 
6.3 Mechanisms of action of levosimendan and OR-1896 
The main mechanism of action of both levosimendan and OR-1896 is considered to be calcium 
sensitization, but additional mechanisms of actions, such as KATP-channel opening and PDE-
inhibiting properties are also involved (Kopustinskiene et al., 2004, Yokoshiki et al., 1997b, 
Yokoshiki et al., 1997a, Takahashi et al., 2000b, Takahashi et al., 2000a, Banfor et al., 2008, Erdei et 
al., 2006). Although this study was not aimed at describing the mechanism of actions for discovered 
findings, based on these it could be argued that calcium sensitization provides only part of the 
beneficial effects during oral levosimendan and OR-1896 treatments. Especially the fact that 
levosimendan was able to significantly suppress apoptosis, which is generally considered to be 
mediated via opening of mitochondrial KATP channels, in both experimental models supports this 
notion. Levosimendan and to a weaker extent OR-1896 are inhibitors of PDE III, but these inhibiting 
properties seem to have only minor significant relevance at clinical doses (Kaheinen et al., 2006, 
Ajiro et al., 2002, Szilagyi et al., 2005, Szilagyi et al., 2004). The irrelevance of PDE inhibition is 
further supported by our study, which showed antiapoptotic effects of levosimendan, while traditional 
PDE inhibitors have been found to have a detrimental effect when given to patients with heart failure 
via an increased level of apoptosis (Ding et al., 2005). Based on our results, further investigations into 
the roles of calcium sensitization, KATP channel opening and PDE inhibition are required. 
 
6.4 Clinical implications and future aspects 
The role of OR-1896 in beneficial effects associated with levosimendan treatment remains unknown. 
OR-1896 has a considerably longer half time (75-78 h in humans, 6.5 h in rats) than levosimendan (1 
h in humans, 0.6 h in rats (Orion Pharma, unpublished information)), indicating that it is responsible 
for long-term, up to 7 days, effects seen after single levosimendan infusion (Kivikko et al., 2003, 
Sandell et al., 1995, Kivikko et al., 2002a). In clinical use, the infusion time of levosimendan has 
been limited to 24 h due to possible cumulation OR-1896. However, previous studies by others and us 
indicate that oral, continuous administration of levosimendan is a safe and effective treatment option 
(Nieminen et al., 2008, Louhelainen et al., 2007). The doses of levosimendan and OR-1896 used, 
yielded plasma concentrations of approximately 6-80 ng/ml for levosimendan and 4-50 ng/ml for OR-
1896, which are at relevant clinical level (Kivikko et al., 2002b). We were unable to detect any 
adverse effects with chronic oral levosimendan or OR-1896 in either of the experimental heart failure 
models used. It could also be argued, that despite mother compound has some additional benefits in 
prevention of mortality, OR-1896 is as effective in treatment of heart failure, at least in rats. 
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Beneficial effects could be mediated via steady plasma level of OR-1896, based on its considerably 
longer half-life. In our study, the plasma concentration of OR-1896 during chronic OR-1896 
administration showed no diurnal fluctuation as was seen during levosimendan treatment. 
Prolonged administration of levosimendan has been associated with side effects, namely hypotonic 
events and atrial fibrillation, most likely due to accumulation of the long-lived active metabolite OR-
1896. Therefore, current clinical recommendations limit the maximal infusion time of levosimendan 
to 24 h. These adverse reactions could be avoided by repeated administrations of levosimendan 
infusion, as Parissis et al. in a small-scale study reported the safety and beneficial effects of serial 
levosimendan infusions on patients with heart failure (Parissis et al., 2006a). However, the costs and 
inconvenience of this time-consuming invasive method of intravenous administration restricts its 
widespread use. Neither levosimendan nor OR-1896, while administered orally in a chronic manner 
showed any signs of adverse reactions or cumulative toxicity. However, the transient decrease in 
blood pressure and the slight increase in heart rate discovered in here could potentially explain side 
effects, such as hypotension and arrhythmias, in human populations. 
Data on oral use of levosimendan remain limited. In the only large-scale study of oral levosimendan 
in humans to date, the PERSIST study, levosimendan failed to show improvement in the novel main 
end-point, Patient journey (Nieminen et al., 2008). However, the PERSIST patients had very severe 
heart failure with recent hospitalizations, very high NT-proBNP values and symptoms at rest or very 
mild exercise, which could, explain the discovered ineffectiveness of levosimendan treatment. The 
PERSIST study also had some problems in baseline imbalance and in patient randomization, pro-BNP 
levels in the lower levosimendan dose group being 40% greater than in controls. Taken together, 
improvements in the quality of life score and in renal function and a reduction in NT-proBNP provide 
encouragement for further studies. 
Even though studies in rats cannot be extrapolated to humans, results of the present study indicate that 
oral levosimendan and OR-1896 provide interesting possibilities in prevention of experimental 
hypertensive heart disease and post-infarct cardiac remodelling as well as other low cardiac output 
conditions such as shock and pre-, peri- and post-operative cardiac interventions. Indeed, 
levosimendan is currently under evaluation in several clinical studies ranging from septic shock to 
weaning from cardio-pulmonary by-pass (ClinicalTrials.gov, 2009). 
Especially the safety of continuous oral administration discovered in this study gives encouragement 
for future development of a suitable oral drug form for man, even though preliminary findings of oral 
levosimendan in humans have been disappointing. Therefore, further studies of the beneficial role of 
oral calcium sensitization in human heart failure of different origins are warranted. 
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7 Conclusions 
 
The aim of this study was to investigate the cardiovascular effects of oral calcium sensitizers 
levosimendan and OR-1896, an active metabolite, in two different models of experimental heart 
failure, namely an experimental model of myocardial infarction induced by coronary artery ligation 
and salt-sensitive model of essential hypertension. These models represent post-infarct heart failure 
and hypertension-induced heart failure with preserved systolic function, respectively. The main 
findings of these non-clinical cardiovascular studies were as follows: 
 
I. Oral treatment with calcium sensitizer levosimendan and OR-1896 improved survival, 
produced a transient decrease in systolic blood pressure, and prevented hypertension-
induced cardiac remodelling, apoptosis and neurohumoral activation in hypertensive 
Dahl/Rapp SS rats on a high-salt diet. Our findings indicate that the beneficial effects of 
oral levosimendan treatment were mediated, to a great extent, by the active and long-lasting 
metabolite OR-1896.  
II. Post-infarct cardiac remodelling in spontaneously diabetic GK rat was associated with 
increased inflammation response, oxidative stress, neurohumoral activation, sustained 
cardiomyocyte apoptosis, increased cellular senescence and disturbances in the expression 
of calcium-handling proteins when compared to post-infarct cardiac remodelling in non-
diabetic Wistar rats. 
III. Oral levosimendan prevented post-infarct cardiac remodelling and restored systolic 
function in both spontaneously diabetic GK rats and non-diabetic Wistar rats. 
Levosimendan did not influence systolic blood pressure, blood glucose level, myocardial 
infarct size or cardiovascular mortality. The cardiovascular effects of levosimendan were 
more pronounced in diabetic rats than in the non-diabetic controls. 
IV. In spontaneously diabetic GK rats with MI, oral OR-1896 restored cardiac functions at 
systole, ameliorated post-infarct cardiac hypertrophy and prevented MI-induced increases 
in cardiac atrial natriuretic peptide (ANP), monocyte chemoattractant protein 1 (MCP-1) 
and connective tissue growth factor (CTGF) mRNA expressions, markers of 
pressure/volume overload, inflammation and fibrosis, respectively. OR-1896 suppressed 
MI-induced cardiomyocyte senescence, but did not influence systolic blood pressure, blood 
glucose level, myocardial infarct size or cardiovascular mortality.  
V. Our results suggest a therapeutic role for oral calcium sensitizers in the prevention of 
hypertension-induced heart failure with preserved systolic function as well as in the 
prevention of post-infarct heart failure with decreased systolic function. 
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